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Abstract 
Endoribonucleases were once thought of as only being key enzymes responsible for 
the degradation of prokaryotic mRNAs. They are now believed to play critical role in 
initiating eukaryotic/mammalian RNA decay and hence RNA abundance. To date, only few 
mammalian endoribonucleases that cleaved mRNA have been identified and studied. It is 
unknown if mammalian endoribonucleases can control microRNA (miRNA) abundance. 
The major goal of this MSc thesis was to develop a high-throughput method to identify new 
human endoribonucleases that cleave miR155. 
The first objective of this thesis was to develop a high-throughput method to 
express and purify human recombinant proteins from the hExl human fetal brain library. 
This was followed by development of a high-throughput fluorescence-based assay to screen 
purified recombinant proteins for activity against fluorogenic miR155 substrate. Through a 
series of optimization experiments, we have successfully established a high-throughput 
procedure and the criteria in selecting a preliminary list of positive candidates. 
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Chapter 1 
Introduction 
In Eukaryotic cells, gene expression is a tightly regulated process with key players 
guarding at different steps. This chapter briefly describes the general key players involved 
in the post-transcriptional control of gene expression with an emphasis on human 
endoribonucleases and mieroRNAs. 
1.1 Mechanisms in the control of Eukaryotic gene expression 
In eukaryotic cells, gene expression can be controlled at transcriptional and post-
transcriptional levels. At the transcriptional level, gene regulatory proteins containing DNA 
binding motif bind to the regulatory sequence of the target gene and regulate the time and 
frequency of gene transcription. For example, p53 and GATA-1 recognize two different 
DNA sequences in target genes in mammalian cell (Alberts et al. 2002). On the other hand, 
transcription can also be turned off completely upon DNA methylation (Alberts et al. 2002). 
In the post-transcriptional stage, RNA turnover which dictates mRNA abundance 
can directly control the abundance of protein (Fan et al. 2002; Raghavan et al. 2002). 
Conventional mRNA decay pathways such as polyA deadenylation, 3'-5' decay and 5'-3' 
decays were generally believed to be the major mode of mRNA degradation (Parker and 
Song 2004). However, this dogma has been challenged by the mRNA specificity of few 
endoribonucleases (Li et al. 2010) and the recent discoveries of endoribonucleases that 
demonstrated endoribonuclease activity of a number of proteins known to be involved in 
exonucleolytic degradation (Tomecki et al. 2010; Lebreton et al. 2008; Schaeffer et al. 
2009). Differences and similarities between these two pathways are illustrated in Figure 1. 
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Figure 1. A schematic diagram of conventional exoribonucleolytic decay pathway and 
hypothetical endoribonucleolytic decay pathway that control stability of mRNA. (A) 
Two major exoribonucleolytic decay pathways. Top: Deadenylase leads to the shortening 
of polyA tail as the initial step of 3'-5' mRNA exoribonucleolytic decay. Bottom: Removal 
of 5'-cap by decapping proteins decreases the susceptibility of degradation. (B) 
Endoribonuclease cleaves mRNA in the middle and accelerates further degradation of 
target mRNA. (C) Further degradations are executed by 3'-5' and 5'-3' exoribonucleases 
(Parker and Song 2004; Garneau et al. 2007). 
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1.2 Key players in the control of RNA degradation 
1.2.1 Enzymes - decapping enzymes, exoribonucleases, endoribonucleases and RBP 
Decapping enzymes 
Decapping enzymes are enzymes that remove the 5'- cap structure of transcript 
(Fillman and Lykke-Andersen 2005). Well studied decapping enzymes include Dcpl/2 and 
DcpS. Dcp 1/2 is part of a processing body complex that hydrolyzes the cap structure 
m7Gppp. Removal of the protective cap leads to further degradation of the mRNA. The 
ability to bind to specific RNA is also essential for the decapping function as exemplified 
by hDcp2 (Li et al. 2008). 
Exoribonucleases 
In the past, exoribonucleases were thought to be the major players in RNA 
degradation. A number of exoribonucleases have been studied in different mRNA decay 
pathways. Exoribonucleolytic degradation takes place after the decapping or 
dephosphorylation of the transcript, from either 5'-3' or 3'-5' direction (Figure 1). Some 
well known examples of exoribonucleases associated with cancers are CCR4b, PARN and 
XRN1. 
CCR4b, a component of human Ccr4-Not complexes, exhibits 3-5' poly(A) 
exoribonuclease and ssDNA exonuclease activities (Lau and MacRae 2009; Chen et al. 
2002; Morita et al. 2007). It regulates the mRNA level of a tumor suppressor gene p27Kipl. 
Depletion of CCR4b can increase the p27Kipl mRNA level and impair cell growth (Morita 
et al. 2007). Poly (A)-specific ribonuclease (PARN) is another exoribonuclease that 
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cleaves from 3'-5' direction. As its name suggests, PARN preferably cleaves the poly (A) 
tails from 3'-direction. It also interacts with the 5'- end cap for a more efficient degradation 
of the poly (A) tails (Gao et al. 2000; Martinez et al. 2001). It participates in nonsense-
mediated mRNA decay and degradation of mRNAs containing AU-rich elements (AREs) 
in their 3'-UTR (Lai et al. 2003). 
Besides deadenylase, the 5'-3' exoribonuclease representative XRNlcan also 
promote mRNA decay. In conventional mRNA decay pathways, upon the decapping of 
mRNA, XRN1 degrades the decapped mRNA from 5'-3' (Mitchell et al. 1997). It was also 
found to be an important factor in the spatial regulation of mRNA decay in mouse 
(Bashkirov et al. 1997). In the absence of XRN1, polyA+ mRNAs accumulate at the 
processing bodies in mammalian cells (Cougot et al. 2004). The XRN1 gene is also a novel 
candidate tumour suppressor gene in osteogenic sarcoma (Mullen et al. 2008; Zhang et al. 
2002). 
Endoribonucleases 
Researchers in the RNA field started to rethink the position of these two types of 
RNases in term of RNA metabolism after more work on endoribonucleases was done. 
Compared to exoribonucleolytic decay, endonucleolytic cleavages demonstrate higher 
sequence specificity (Rodgers et al. 2002, Stevens et al. 2002, van Dijk et al. 2000). One 
important aspect to consider is that many RNA therapeutic approaches, such as antisense 
therapy and therapeutic RNA interference, involve specific RNA sequence and 
endoribonucleolytic activity. 
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Many of the known endoribonucleases are discovered by chance. A recent review 
on endoribonuclease concludes that no share protein domains for endonucleolytic RNA 
cleavage were found in most of the 13 enzymes discussed; structural diversity was found 
for those that did have identified ribonuclease domains (Li et al., 2010). Regardless of their 
dissimilarity, these known endoribonucleases have been found to play important roles in 
essential cellular processes such as RNA interference, ER stress response, viral defence, 
aberrant RNA surveillance, microRNA biogenesis, tRNA processing, signalling and 
angiogenesis. 
Associations between endoribonucleases and cancers have been shown previously 
by several examples such as Argonaute 2, IREl, APEl G3BP, Drosha and Dicer (Kim et al. 
2009). These examples provided evidence that induction or suppression of such enzymes 
control toward the development of diseases such as cancers. More detailed descriptions of 
relevant human endoribonucleases are discussed in Section 1.4. 
RNA-bindlne proteins (RBP) 
Beside the enzymes that cleave RNA, RBPs also play important role in post-
transcriptional control of gene expression. One of the main functions of these proteins are 
to block the interaction of the target mRNA with other proteins. AU-rich mRNAs are often 
the target of RNA binding protein regulation. Studies have found one single enzyme, 
tristetraprolin (TTP), to be the key regulator of a group of 63 genes which have AU-rich 
mRNA and are implicated in cellular growth, invasion and metastasis (Al-Souhibani et al. 
2010). Furthermore, exemplified by transactivation-responsive RBP/ TRBP, RBP is also 
found to post-transcriptionally control the biogenesis of microRNA (Chendrimada et al. 
2005; Melo et al. 2009; Paroo et al. 2009). 
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RBPs can bind to protect and control stability of the target RNA. For instance, HuR 
plays an important role in the growth of cancer cells. In MCF7 human breast cancer cell 
lines, it increases the stability of GATA3 and ER mRNA (Licata et al. 2010; 
Pryzbylkowski et al. 2008). In human conventional renal cell carcinoma (CRCC), HuR is 
overexpressed and stabilizes mRNA for proteins that are crucial for human CRCC 
tumorigenesis (Danilin et al. 2010). 
The c-myc coding region determinant-binding protein (CRD-BP) is another 
example of RBP found highly expressed in various types of human cancer including breast, 
colon, skin, ovary, lung, brain and testicular cancer (Doyle et al., 2000; Ioannidis et al., 
2003; Dimitriadis et al., 2007; Ross et al., 2001; Kobel et al., 2007; Hammer et al., 2005; 
Ioannidis et al., 2005; Elcheva et al., 2008; Ioannidis et al., 2004). CRD-BP has been 
shown to bind to and stabilize a number of mRNAs implicated in cancers. The mRNA 
targets of CRD-BP are c-myc, CD44, pTrCPl, IGF-II, P-catenin, GLI1, and MDR1 
(Ioannidis et al. 2005; Sparanese and Lee 2007; Vikesaa et al. 2006; Noubissi et al. 2006; 
Leeds et al. 1997; Gu et al 2008; Noubissi et al. 2009). 
While HuR and CRD-BP promote the growth of cancer cells, there are RBPs that 
play the opposite role by suppressing cancer growth. They are exemplified by proteins in 
the quaking family which is composed of multifunctional mRNA regulators that function 
as tumour suppressors (Biedermann et al. 2010). 
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1.2.2 Cellular structures involved in mRNA degradation 
Stress granule (SG) 
SGs belong to a type of the RNA granule groups involved in RNA translational 
regulation and decay. The SGs rapidly accumulate within 15-30 minutes as a stress 
response upon environmental stresses (Anderson and Kedersha 2006). The stability of 
specific mRNAs is regulated by the selective recruitment into the SGs, and the translational 
rate is subsequentially controlled (Anderson and Kedersha 2002). Components of SG 
include a wide range of protein classes such as ribosomal, translational proteins, proteins 
involved in RNA stability, RNA-binding proteins, exonucleases and enzymes from the 
RNAi pathway (Anderson and Kedersha 2006; Kedersha et al. 2005; Kedersha et al. 2002; 
Kedersha et al. 1999; Wilezynska et al. 2005; Stoecklin et al. 2004; Gallouzi et al. 2000; 
Thomas et al. 2005; Hua and Zhou 2004; Tourriere et al. 2003). 
Processing-body (PB) 
PB is one of the major compartments involved in mRNA degradation in cytoplasm. 
They interact closely with the SGs. mRNA marked by destabilizing factors may be 
transferred from SGs to PBs for degradation (Anderson and Kedersha 2008). It is also a site 
for RNA interference to take place (Lian et al. 2006; Jakymiw et al. 2005). 
PBs contain enzymes which carry out the mRNA degradation functions including 
deadenylation, decapping, exoribonucleolytic and endoribonucleolytic decay (Eulalio et al. 
2007; Franks et al. 2008; Parker and Sheth 2007). The degradation function begins with 
deadenylation of the poly A tail of the target transcript by the Ccr4p/Pop2p/Not complex, 
which is required for the PB formation (Parker and Sheth 2007; Zheng et al. 2008). After 
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deadenylation, two major decays take place from either direction of the transcript: 3' to 5' 
degradation carried by exosome and 5' to 3' degradation by exoribonuclease Xralp 
following removal of the m7Gppp cap by Dcpl/2 (Gu et al. 2004; Parker and Sheth 2007) 
or DcpS (Gu and Lima 2005). PBs are also composed of microRNA repression factors 
such as Argonautes and RNA binding proteins and translation repressors (Parker and Sheth 
2007). 
RNA-Induced Silencing Complex (RISC) 
The RISC has received a great deal of attention since its discovery in 1985, due to 
its ability to repress target gene expression by degrading respective mRNA transcript (van 
den Berg et al. 2008; Rosenberg et al. 1985). It is a multi-protein complex that controls 
gene expression in translational level. Minimal components of RISC include a main 
catalytic component Argonaute 2 and a guide strand RNA that is either a microRNA or 
siRNA. The guide strand is either partially or completely complimentary to the target 
mRNA. Pairing of these two strands will result in translational repression or mRNA 
degradation (Huntzinger and Izaurralde 2011). The cleaved mRNA is then released and 
subjected to further exoribonucleolytic degradations. 
Exosome 
The exosome, also called PM/Scl complex, is a well known and characterized 
complex cellular structure that degrades RNA in 3'-5' direction. Specific exoribonucleases 
in the exosome are hRrp4p, hRrp40p, hRrp41p, hRrp46p, hMtr3p, Hrrp42p, oIP2, PM/Scl-
75, PM/Scl-100 and Rppl4 (Raijmakers et al. 2004). Beside its main role in 
exoribonucleolytic activity, it is recently found that the exosome also contains proteins 
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with specific endoribonuclease and cytoplasmic mRNA decay activities (Schaeffer et al. 
2009). The complex is also composed of proteins with RNA binding, 3'-5' hydrolytic 
exoribonuclease, 3'-5' phosphorolytic exoribonuclease, RNA helicase and nucleotide 
binding activities (Raijmakers et al. 2004). 
In eukaryotes, the exosome is known to contribute to ribosomal RNA and small 
RNAs processing, pre-mRNA quality control and mRNA turnover (Raijmakers et al. 2004). 
Exosome mediated RNA degradation is sequence specific. For example, mRNAs with AU-
rich elements are targeted by the exosome mRNA degradation (Mukheijee et al. 2002). 
1.2.3 non-coding RNA 
Another group of trans-acting factors that control the expression of genes is the 
non-coding RNAs (ncRNAs). They are abundant in mammalian cells (Mattick and 
Makunin 2006). RNAs that belong to this group include rRNA, tRNA, snRNA, snoRNA, 
microRNA and siRNA (Mattick et al. 2006). They fall into two categories according to 
their function: infrastructural ncRNAs (rRNA, tRNA, snRNA and snoRNA), and small 
regulatory ncRNA (snoRNA, microRNA and siRNAs) (Mattick et al. 2006). Increasing 
evidence indicates the association of ncRNAs with different types of cancers, which 
warrant their possible use as therapeutic target (Mallardo et al. 2008). 
1.3 Significance of microRNA in the control of gene expression 
MicroRNAs are a type of non-coding RNAs with the length of 18 - 24 nt that post-
transcriptionally regulate the expression of genes. This group of small RNA has gained 
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great attention after its discovery in 1993, mainly due to its important role in the regulation 
of gene expression in the RISC. 
1.3.1 MicroRNA Biogenesis 
MicroRNAs are produced in a highly regulated manner (Siomi and Siomi 2010). 
They are generated from a microRNA gene or from the intron of a protein coding gene that 
is also called a mirtron (Chekulaeva and Filipowicz 2009; Kim et al. 2009). Four 
complexes (the microprocessor complex, the nuclear export complex, the Dicer complex 
and the RISC) are involved in the biogenesis and action of microRNA. In the nucleus, 
primary microRNA or pri-microRNA is generated, through the tailoring of Drosha 
containing microprocessor complex (Han et al. 2004; Gregory et al. 2004; Denli et al. 
2004). Pri-microRNA is cropped by Drosha to form the hairpin shaped pre-microRNA. The 
pre-microRNA is then transported out of the nucleus to the cytoplasm by the nuclear export 
complex composed of Exportin 5 and RAN. In the cytoplasm, the Dicer complex further 
cuts the pre-microRNA into its mature form; the mature microRNA is functional as part of 
the RISC (Ryan et al. 2010; Ahluwalia et al. 2009). 
1.3.2 Regulatory roles of microRNA 
MicroRNAs control gene expression through either translational repression or 
degradation of mRNA (Cai et al. 2010; Esslinger et al. 2009). They have a huge impact on 
the global expression of proteins (Baek et al. 2008); about half of all mammalian protein 
coding genes are predicted to be controlled by these versatile regulatory elements (Krol et 
al. 2010). Targets of microRNAs include functionally related effector genes, regulators of 
transcription and regulators of alternative splicing (Makeyev and Maniatis 2008). 
9 
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MicroRNAs have also been found to be involved in skin morphogenesis (Yi and Fuchs 
2010), signal transduction (Inui et al. 2010) and glucose and lipid metabolism (Lynn 2009). 
1.3.3 Role of microRNA in cancer 
MicroRNAs are broadly implicated in various types of diseases, particularly cancer. 
The role of microRNA in cancer can be placed into two categories - oncogenic and tumour 
suppressor microRNA (Zhang et al. 2007). Oncogenic microRNAs that capture much of 
the attention are over-expressed in many types of cancers; this is exemplified by miR155 as 
the first oncogenic microRNA discovered (Tong and Nemunaitis 2008; Tam and Dahlberg 
2002). MiR155 was found to inhibit apoptosis by suppressing Caspase-3 and apoptosis 
related enzymatic activity (Ovcharenko et al. 2007; Gironella et al. 2007). It is up-
regulated in several types of cancers including CLL (chronic lymphocytic leukemia), breast 
cancer, Burkitts lymphoma, Hodgkins lymphoma, B-cell lymphoma, lung cancer, and 
pancreatic cancer (Iorio et al. 2005; Faraoni et al. 2009; Zhang et al. 2007; Rai et al. 2008; 
Tong and Nemunaitis 2008; Yue and Tigyi 2006; Wiemer 2007). Because of the widely 
distributed oncogenic activity of miR155 in a number of malignancies, it serves as an 
excellent target for cancer therapy. Thus, miR155 was chosen as a target RNA in this 
research. 
1.3.4 Regulation of microRNA abundance 
Though much evidence has shown the regulatory roles of microRNA in a wide 
variety of cellular activities, the expression and turnover of microRNAs are also under 
sophisticated regulations. The microRNA abundance can be controlled in two major ways: 
through the regulation of microRNA biogenesis and microRNA decay. 
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Primary microRNAs (pri-miRNA) are generated from microRNA gene 
transcription by RNA polymerase II (Kim et al. 2009). The transcriptional control of the 
microRNA gene is quite similar to the protein-coding gene. These two types of gene share 
similar features in the promoter regions, such as GpG islands, TATA box sequences, 
initiation elements and histone modifications (Ozsolak et al. 2008; Corcoran et al. 2009). 
These similarities suggest that transcription factors (TFs), enhancers, silencing elements 
and chromatin modifications are the key controllers in microRNA gene transcription (Krol 
et al. 2010). 
After transcription, pri-miRNAs are cleaved by Drosha in the microprocessor 
complex in the nucleus (Han et al. 2004; Gregory et al. 2004; Denli et al. 2004). Pri-
miRNAs become precursor microRNAs (pre-miRNAs) after removal of part of the stem. 
The pre-miRNAs are then exported from the nucleus. In the cytoplasm, pre-miRNAs are 
further processed by Dicer to remove the loop to generate a major and a minor mature 
microRNA. The major strand is loaded onto Argonaute located in the RISC as a guide for 
gene silencing. Differential expressions of microRNAs in different tissues and during 
different developmental stages suggest that microRNA biogenesis can be regulated (Davis 
et al., 2009; Ding et al., 2009; Ambros et al, 2003; Wulczyn et al, 2007). 
Besides regulation of microRNA biogenesis, the microRNA abundance is also 
controlled by their turnover. Compared to biogenesis and regulatory control of microRNA, 
current available information regarding the control of microRNA stability is still very 
limited. Nonetheless, some progress has been made to find the key players in microRNA 
degradation. Several studies have found evidence of acceleration and regulation in selected 
microRNA turnover (Krol et al. 2010; Hwang et al. 2007; Buck et al. 2010; Sethi and 
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Lukiw 2009; Rajasethpathy et al. 2009). The first two exoribonucleolytic degradation 
models of microRNA decay were found in studies using model species, Arabidopsis 
thaliana and Caenorhabditis elegans. In A. thaliana, small RNA degrading nuclease 1 
(SDNl) acted directly toward single stranded miR173 in vitro (Ramachandran and Chen 
2008). Increased stability of several microRNAs (miR159, miR167, and miR173) after 
knockdown of the members from this 3'-5' exoribonuclease family indicated that these 
microRNAs may share a similar RNA decay pathway (Ramachandran and Chen 2008). 5-
3' Exoribonuclease 2 (XRN-2) from C. elegans is the second exoribonuclease discovered 
(Chatterjee and GroBhans 2009). It is a 5'-3' exoribonuclease that carries out the 
degradation of mature let-7 microRNA in vivo (Chatteijee and GroBhans 2009). This 
function of XRN-2 depends on the target availability; the 5'-end of microRNA has to be 
released from miRISC in order to be accessible for XRN-2 (Chatterjee and GroBhans 2009). 
The evidence of microRNA degradation by exoribonucleases was also found in 
human cells. In a recent study conducted with human melanoma cells, miR221 was shown 
to be degraded by a 3'-5' exoribonuclease, human polynucleotide 
phosphorylase/Zz/WPase0'^5 (Das et al. 2010). Another recent study using human 
embryonic kidney 293 cells revealed involvement of the exosome in the degradation of 
miR382 (Bail et al. 2010). 
RBP also play a role in the abundance of microRNA. This is exemplified by a 
human nuclear factor named TDP-43 (Buratti et al. 2010). It can up- or downregulate 
different microRNAs base on the position it binds to. It stabilizes the let-7b by binding to 
the mature form sequence, and decreases the abundance of mature form miR663 by binding 
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to its hairpin precursor (Buratti et al. 2010). Binding to Argonaute proteins in the RISC is 
also thought to protect the microRNA from degradation (Chatteijee and GroBhans 2009). 
Furthermore, a small number of cis-acting elements that affect the microRNA 
stability have also been identified. In animals, 3'-terminal adenylation by GLD-2 was 
found to stabilize mature miR122, but not pre-miR122 (Katoh et al. 2009). In plants, both 
2'-0-methylation and adenylation at 3'- terminal demonstrated stabilizing effect on 
microRNA (Yu et al. 2005; Lu et al. 2009). Known key players regulating animal 
microRNA turnover are shown in Figure 2. It is believed that microRNA degradations are 
likely to be similar to those of mRNAs (Krol et al. 2010). 
Mature microRNA levels do not always correlate with their pri- or pre-mRNAs. 
The evidence of selected mature microRNA turnover strongly supports the existence of 
post-transcriptional mechanisms that control the level of mature microRNA. It is possible 
that endoribonucleolytic cleavage plays a role in the process of microRNA degradation. 
However, due to the lack of information in this area, other key players in microRNA decay 
have yet to be identified and characterized. 
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XRN2 
Argonaute 2 
TDP-43 
hPNPase old-35 
exosome 
B 
5' 3'AA 
GLD2 
Figure 2. Schematic diagram summarizing key factors regulating animal microRNA 
turnover. (A) Binding of RBP (Argonaute 2 or TDP-43) prevents the exoribonucleolytic 
decay from either ends by exoribonucleases (XRN2 or hPNPaseold-35) or exosome. It may 
also compete with unknown endoribonucleases and prevent them from cleaving in the 
middle of microRNA. (B) Adenylation at the 3'-end stabilizes microRNA. 
1.4 Human endoribonuclease 
One of the reasons for our limited knowledge on mammalian endoribonucleases is 
the lack of tools used to identify them. Most of the recent endoribonuclease discoveries 
were quite random. A recent review has focused on comparing the different eukaryotic 
endoribonuclease. It was found that some of the enzymes with known domains demonstrate 
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structural diversity (Li et al., 2010). Endoribonucleases can be associated with a wide 
variety of cellular functions; they may have different mRNA targets, and possess different 
cleavage specificity (Li et al., 2010). In this section, mRNA targets, cleavage specificity 
and cellular functions of known human endoribonucleases are briefly introduced. 
1.4.1 Human endoribonuclease implicated in cancers 
Areonaute 2 (Ago2) 
Ago2, also called Eukaryotic translation initiation factor 2C 2 (eIF-2C 2), is an 
important component in RISC and required for RNA mediated gene silencing (Liu et al. 
2004). Ago2 binds to a guide RNA, either a microRNA or siRNA, in the RISC to target a 
complementary mRNA (Liu et al. 2004; Kim et al. 2009; Carthew and Sontheimer 2009; 
Jinek and Doudna 2009). The binding of the complementary mRNA with the RISC will 
then result in gene silencing by inhibiting the translation or cleaving the complementary 
mRNA (Hutvagner and Zamore et al. 2002; Jinek and Doudna 2009). The interaction of 
Ago2 with Dicer also suggests a role in microRNA biogenesis (Maniataki and Mourelatos 
2005; O'Carroll et al. 2007). Increased level of Ago2 was found in aggressive breast 
tumours (Blenkiron et al. 2007). Also, increased cell proliferation was observed in Ago2 
transfected MCF7 cell line (Adams et al. 2008). 
Inositol-reauiring enzyme 1 (IRE1) 
IRE1 is also called endoplasmic reticulum-to-nucleus signalling protein. It is a bi-
functional protein that has both endoribonuclease and serine/threonine-protein kinase 
activity (Tirasophon et al. 1998). In mammalian cells, IRE1 is required for a stress 
response pathway functioning under ER stress (Tirasophon et al. 1998). It carries out 
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translational repression by cleaving 28S ribosomal RNA under ER stress (Iwawaki et al. 
2001). IRE1 plays both tumorigenic and tumour suppression roles in tumorigenesis through 
the activation of unfolded protein response by the IREl-XBPls pathway (Kim and Lee 
2009). The IRE1 activity was found to increase the cancer survival and progression in 
several types of cancer, including breast cancer, liver cancer and myeloma (Lin et al. 2007; 
Gomez et al. 2007; Davies et al. 2008; Shuda et al. 2003; Li et al. 2007; Carrasco et al. 
2007). Several observations demonstrating the ability of IRE 1 in inducing cancer cell death 
and inhibition supported the tumor suppression role of IRE 1 in cancer (Kim and Lee 2009; 
Davenport et al. 2007; Guichard et al. 2006; Little et al. 2007; Kraus et al. 2008; Joung et 
al. 2007; Gao etal. 2008). 
RNase L 
RNase L, commonly named 2-5A-dependent ribonuclease, is a 2'-5'-
oligoadenylate- dependent ribonuclease that cuts single stranded RNA (Liang et al. 2006). 
It functions as a viral defense following the activation of interferon (IFNs) pathway 
through a combination of mechanisms by directly degrading viral RNAs and rRNA, and 
inducing apoptosis and other antiviral genes (Le Roy et al. 2001). 
RNase L also contributes to tumor suppressor activities such as stress mediated 
apoptosis cell proliferation and regulation of protein synthesis (Liang et al. 2006, Madsen 
et al. 2008). Mutated RNase L was related to the increased risk of head and neck, uterine 
cervix, breast and prostate cancer (Madsen et al., 2008; Carpten et al., 2002). 
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APE1 
Apurinic/apyrimidinic (A/P) DNA endonuclease APE1, also called APEX-1 in 
humans, is commonly known as a DNA repair enzyme that cleaves A/P DNA in base 
excision repair mechanism. Other known functions of APE1 include redox activation of 
transcription factors, 3'-phosphodiesterase, 3'-5' exonuclease, 3' phosphatase, and RNase 
H activities (Chou and Cheng 2002, Tell et al. 2005). It was recently discovered as an 
endoribonuclease that binds to a coding region of c-myc mRNA called the coding region 
determinant (CRD) and preferentially cleaves phosphodiester bonds between UA, CA and 
UG dinucleotides (Barnes et al. 2009). The cancer types previously reported to be 
associated with APE1 are myeloma, osteosarcoma, hepatocellularcarcinoma, breast 
carcinoma, colon adenocarcinoma, lung adenocarcinoma and leiomyoma (Kim and Lee 
2009; Tell et al. 2005; Yang et al. 2007; Wang et al. 2004; Pardini et al. 2008; De Ruyck et 
al. 2007; Orii et al. 2002). The implications of APE1 with cancer may be linked to its 
ability to control c-myc gene expression level by cleaving its mRNA (Kim and Lee 2009; 
Barnes et al. 2009). 
Drosha and Dicer 
Drosha and Dicer are both members of the RNase III family. Drosha processes 
primary microRNA (pri-microRNA) as a component of the microprocessor complex in the 
nucleus (Han et al. 2004; Gregory et al. 2004; Denli et al. 2004). It cleaves double stranded 
pri-microRNA at the 3'- and 5'- ends and produces precursor microRNA (pre-microRNA) 
(Lee et al. 2003). Dicer comes in to carry out dsRNA cleavage and generate siRNA or 
premature microRNA by cleaving the hairpin pre-mRNA (Fortin et al. 2002, Nicholson 
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and Nicholson 2002, Doi et al. 2003, Zhang et al. 2004). A recent study also suggests that 
Drosha and Dicer are involved in rRNA biogenesis (Liang, 2011). The major implication 
of Drosha and Dicer in cancer mainly comes from their functions in microRNA processing 
and biogenesis by increasing the levels of oncogenic microRNA (Nakamura et al. 2007; 
Davis et al. 2008; Iorio et al. 2005; Roldo et al. 2006; Slaby et al. 2007; Dillhoff et al. 
2008; Markou et al. 2008; Connolly et al. 2008; Chiosea et al. 2006; Chiosea et al. 2007; 
Chiosea et al. 2008; Flavin et al. 2008; Kaul et al. 2004). 
G3BP 
G3BP was identified as a cytosolic protein that binds to Src homology 3 (SH3) 
domain of GTPase-activating protein (GAP) (Parker et al. 1996). It binds to GAP only in 
proliferating cells where Ras is in the activated state (Parker et al. 1996, Tourriere et al. 
2001). Endoribonucleolytic activity of G3BP occurs at the phosphodiester bond in between 
CA dinucleotide of 3' UTR of c-myc mRNA (Tourriere et al., 2001). Its high-affinity 
binding to polyA mRNAs sequence appears to allow the mRNA to decay with specificity 
as exemplified by the cleavage of 3'UTR of human c-myc mRNA (Tourriere et al. 2001, 
Gallouzi et al. 1998). Two isoforms of this RNase, G3BP1 and G3BP2 also bind to p53 
both in vitro and in vivo, and results of the knockdown experiment suggest their negative 
regulation of p53 by regulating a p53 regulator MDM2 (Kim et al. 2007). Expression of 
G3BP is also closely related to lymph node metastasis in esophageal squamous carcinoma 
(Zhang et al. 2007). 
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Angiogenin 
Angiogenin, also known as RNase 5, belongs to the pancreatic ribonuclease family 
with 65% homology to pancreatic ribonucleases RNase A (Saxena et al. 1992). Compared 
to RNase A and other known eukaryotic endoribonuclease, Angiogenin has much weaker 
activity (Li et al. 2009; Kelemen et al. 1999). However, despite its weak enzymatic activity, 
Angiogenin has great biological significance. It is a cytotoxic RNase that inhibits protein 
synthesis by degrading cellular tRNAs, and both 28S and 18S ribosomal RNA (Saxena et 
al. 1992; Lee and Vallee 1989; Shapiro et al. 1986). The level of angiogenin is found to be 
elevated in prostate cancer, gastric carcinoma and melanoma (Katona et al. 2005; Chen et 
al. 2006; Vihinen et al. 2007). 
Flap structure-specific endonuclease 1 (FENl) 
FEN1, similar to APE1, is an important multi-functional protein in DNA repair and 
base-excision repair (Robins et al. 1994; Shen et al. 1996; Guo et al. 2008). It also exhibits 
5-3' exonuclease activity toward double stranded DNA, RNase H activity and 
endonucleolytic cleavage of RNA at 5' endogenous stem structures (Robins et al. 1994; 
Shen et al. 1996; Guo et al. 2008; Stevens et al. 1998). Its association with cancer has been 
linked to its DNA endonuclease activity (Kim and Lee 2009). However, its 
endoribonuclease activity has not been associated with cancer. 
PoMUl-specific endoribonuclease 
This protein is also called Placental protein 11 (PP11), as it is placental specific 
(Bohn and Winckler 1980; Bohn et al. 1981). It belongs to the ENDOU family and cleaves 
single stranded RNAs and results in products containing 2'-3'- cyclic phosphate termini 
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(Laneve et al. 2008). PP11 is a tumour marker with diagnostic significance (Grundmann et 
al. 1990), and has been found to express in various type of cancer including mucinous and 
serous cystadenocarcinoma (Inaba et al. 1982), breast cancer (Inaba et al. 1981), and 
gastric cancer (Inaba et al. 1980). 
1.4.2 Human endoribonucleases that belong to a complex 
Some endoribonucleases take part in a complex to achieve their functions. The 
endoribonucleases Argonaute 2, Dicer and Drosha that have already been mentioned in 
Section 1.4.1 also belong to this group. Both Argonaute 2 and Dicer are components of the 
microRNA loading complex (miRLC) of RISC and are required for biogenesis and 
recruitment of microRNA (MacRae et al. 2008), while Drosha is part of the microprocessor 
complex (Han et al. 2004; Gregory et al. 2004; Denli et al. 2004). The rest of this group is 
exemplified by CPSF3, SMG6 and Rrp44. 
CPSF3 
CPSF3 is a component of the cleavage and polyadenylation specificity factor 
(CPSF) complex. It possesses both endoribonuclease and exoribonuclease activities. 
CPSF3 plays a key role in the histone 3'-end pre-mRNA processing by cleaving the histone 
pre-mRNAs and carrying out exoribonucleolytic degradation of the downstream cleavage 
product from the 5' to 3' direction (Ryan et al. 2004; Kolev et al. 2008; Mandel et al. 
2006). It also recognizes the AAUAAA signal sequence and interacts with PolyA 
polymerase and other factors to implement the cleavage and polyA addition (Kaufmann et 
al. 2004). 
20 
CH 1 INTRODUCTION 
SMG6 
SMG6, also called Telomerase-binding protein EST1 A, is part of the telomerase 
ribonucleoprotein (RNP) complex. It functions as an endonuclease and cleaves single 
stranded RNA, but not double stranded RNA or single stranded DNA (Snow et al. 2003; 
Glavan et al. 2006). It exemplifies the involvement of endoribonucleases in the mRNA 
surveillance mechanism by cleaving nonsense mRNA in human cells (Eberle et al., 2009). 
Rrp44 
Rrp44 (Ribosomal RNA-processing protein 44, also called Dis3-like 1), is a 
component of the exosome complex that plays key role in RNA processing and turnover. It 
has recently been discovered that Rrp44 has both 3'-5' exoribonuclease and 
endoribonuclease activities (Tomecki etal. 2010). 
1.4.3 Other human endoribonucleases 
RNase K 
RNase K is a relatively new ribonuclease. The human ortholog of RNase K is a 98 
amino acid protein that cleaves specifically at ApU and ApG phosphodiester bonds, and 
also UpU at a lower rate (Economopoulou et al. 2007). 
ARD-l/NIPP-1 
ARD-1 (Activator of RNA decay) is a site-specific Mg2+ dependent 
endoribonuclease that has a similar cleavage functionally resembling RNase E from E. coli; 
it cleaves the same substrate as RNase E in vitro at the same cleavage site. ARD-1 was first 
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discovered in the expression of human cDNA copy of ARD-1 (Claverie-Martin et al. 1997), 
and it was later found to be an isoform to NIPP-1 encoded from the same gene by 
alternative splicing (Chang et al. 1999). 
Pancreatic RNase 
The pancreatic ribonuclease family is probably the most extensively studied RNase 
across different species. The RNase A superfamily is one of the most intensively studied 
ribonuclease with diverse members from RNase 1-13, which are mainly responsible for 
host defense (Dyer and Rosenberg 2006). Other biological processes that RNase A 
contributes to are neurotoxicity, angiogenic activity, immunosuppression and anti-tumour 
activity (Beintema et al., 1988; Di Donato et al., 1993). 
1.4.4 Summary 
It is believed that endoribonucleases closely regulate the abundance of mRNA or 
microRNA in cells. However, very little information is known regarding the specific 
mRNA and microRNA endoribonucleases regulate. Only a few human endoribonuclease 
described in the earlier sections possess specificity toward a particular mRNA. For instance, 
IRE1 specifically cleave XBP1 mRNA during splicing to generate a new C-terminus as an 
unfolded protein response (Iwakoshi et al., 2003; Lee et al., 2002). In addition, IRE1 also 
cleave non-mRNA, 28S ribosomal RNA. APE1 is shown to cleave c-myc mRNA at its 
CRD region (Barnes et al., 2009). As mentioned above, G3BP binds and cleaves the 3'-
UTR of c-myc mRNA (Tourriere et al. 2001, Gallouzi et al. 1998), while Angiogenin 
possess substrate specificity toward cellular tRNAs, and both 28S and 18S ribosomal RNA 
(Saxena et al. 1992; Lee and Vallee 1989; Shapiro et al. 1986). 
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To date, no endoribonuclease has been found to cleave on microRNA directly in 
cells. For the endoribonucleases that have been shown to carry substrate specificity, it still 
remains unknown whether these enzymes can act on other RNAs and influence biological 
functions relevant to the RNA. Therefore, a better understanding of mammalian 
endoribonucleases is required for us to answer these questions. 
1.5 Research objectives 
There is an increasing interest in the regulatory roles of microRNAs in cancers. To 
date, characteristics of inhibitory and regulatory targets of microRNAs have been the main 
focus of microRNA research. In contrast, less effort has been put in finding the key players 
in the regulation of microRNA abundance, especially the degradation of microRNA. It is 
already known that exoribonucleases can catalyze the degradation of microRNA as 
described in Section 1.3.4. No research has been done to find out whether any 
endoribonucleases play a role in accelerating the decay of microRNAs. 
One of the major hindrances to identifying endoribonucleases is the difficulty in 
detecting mRNA or microRNA cleavage products. Hence, despite the increasing 
importance of mammalian endoribonucleases, a great proportion of information about them 
still remains unknown. To this end, this thesis was undertaken in an effort to develop a 
robust fluorescence-based system to identify new human endoribonuclease that can 
potentially degrade oncogenic microRNA. 
The first objective of this thesis was to develop a high-throughput fluorescence-
based method to screen a library of human recombinant proteins for endoribonclease 
activity. To achieve this goal, we chose miR155 as the microRNA target in the high-
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throughput screen. Five 96-well sets containing clones of the human fetal brain cDNA 
library, hExl were randomly chosen. In the first part of this objective, we optimized some 
experimental conditions in the high-throughput system. The second part of this objective 
was to obtain a list of positive hits. Following were the questions that we aim to answer as 
we accomplish the objective: 1. Is the substrate designed suitable based on the screening 
results? Given that there is no known endoribonuclease that cleaves microRNA, is it 
feasible to use microRNA as a substrate for endoribonuclease screen? 2. What is the 
average rate of positive hits from one set? Is it possible that the tested clones are going to 
be all negative or all positive? 3. How do we distinguish between positive and negative hits? 
The second objective of this thesis was to verify the positive hits obtained from the 
primary screen in the first objective. The primary screen step has the potential to pull out 
endoribonuclease, exoribonuclease and RBP, but our primary goal is to find novel 
endoribonucleases. The first part of the second objective, which was essentially our 
secondary screen process, was accomplished by determining the inducibility and purity of 
clones, by further repeating the fluorescence-based assay to reproduce the data from 
primary screen, and obtaining identity and integrity of clones. The second part of the 
second objective was carried out by performing electrophoretic assays using three 
radiolabeled substrates. Two of these radiolabeled substrates used in the electrophoretic 
assay resemble the fluorescence-based substrates used in the primary screen. To find out 
whether the candidate was a potential exoribonuclease, a fourth substrate composed of 15 
adenosine monophosphates was used. 
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Development of a High-Throughput System to express 
and purify a library of recombinant proteins 
2.1 Introduction 
A high-throughput system (HTS) is a type of experimental design that allows 
parallel assay with multiple samples. It is commonly used in drug discovery, chemical, 
biological and biochemical compound discovery. 
2.1.1 Protein Functional Screen 
High-throughput methods that have been proven to be useful for protein functional 
analysis are in increasing demand. In the past, several in vitro protein functional screens 
were successfully developed by different labs (Galicia-Vazquez et al. 2009; Kijanka et al. 
2009; Mouratou et al. 2002; Woo et al. 2005; Proudfoot et al. 2008). Nucleic acid related 
enzymatic functions that have been screened for in these studies include endonuclease 
activity toward DNA substrate, nucleic acid binding and methyltransferase acitvities. In the 
endonuclease and methyltransferase studies, enzymatic activities were screened using 
biotin and digoxingenin labeling methods and determined by ELISA (Mouratou et al. 2002; 
Woo et al. 2005). All of these studies involved substrate labeling. This indicates the 
common use of substrate labeling in protein functional screen. 
2.1.2 cDNA expression library 
The cDNA expression library, hExl (prefix MPMGp800, Imagenes GmbH), used 
in this project contains 35,000 clones that express His-tagged human fetal brain 
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recombinant proteins (Bussow et al. 2000). It was made by inserting cDNAs generated 
from human fetal brain tissue directionally into an expression plasmid, pQE30NST, in 
between restriction sites Sail and NotI (Figure 3). The hExl clones were placed in 384-well 
plates. Each plate contained 4 sets (A-D). In this thesis, the code of hExl clones is in a 
format that the first three letter/digits represent position of the clone in the 384 plate and 
the last three digits represent the plate number. For example, "123512" is clone 123 from 
plate 512. 
P-T5 IacO IacO MRGS;His)6 fiamHI P-SP6 fig/ll P-T7 Wort 
5 Promoter 
6xHis MCS-7 
>4 Lambda terminator 
PQE30NST 
3494 
;l 
Figure 3. Map of the pQE30NST plasmid. 
The hExl library was designed and shown to be suitable for protein characterization 
of the human proteome (Bussow et al. 2004). Another study also showed the application of 
hExl recombinant proteins in a high-throughput screen for antibody binding specificity 
(Kijanka et al. 2009). 
26 
CH 2 DEVELOPMENT OF A HIGH-THROUGHPUT SYSTEM 
There are several potential advantages in using hExl. First, as some tumor 
suppressor genes and oncogenes are found to be expressed only during fetal development 
(Dean 1998), using proteins expressed in human fetal brain may increase the chance of 
finding endoribonuclease implicated in cancer. Second, as the expression-ready cDNA is 
already inserted in the plasmid, cloning step is not necessary. Third, it is known that some 
hExl proteins may be in truncated form (Bussow 2000). Hence, it is possible to produce 
portions of proteins which are soluble and possess endoribonucleolytic activity. 
2.1.3 Expression and purification of sets 512A, 517A, 523C, 525A and 568D 
We developed a high-throughput method to express and purify 480 hExl clones 
from selected sets 512A, 517A, 523C, 525A and 568D, through the optimizations of 
recombinant protein induction, purification, dialysis, and cell lysis. The development of 
this high-throughput system for generating recombinant proteins used in the functional 
screen is described in this chapter. 
2.2 Methodology 
2.2.1 Protein expression using two different sets of media 
1) Preparations 
2YT and SB broth 
Inoculation of the E.coli bacterial culture was performed using a 96-pin replicator 
to transfer a set of frozen hExl clones from 384-well stock plate to four 96-well tissue 
culture plates. Each of the 96 well contained 100 \iL 2YT with perspective antibiotics (100 
(ig/mL ampicillin and 15 jig/mL kanamycin). Glucose (2%) was added to the broth to 
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ensure the healthy growth of small size cultures. These starter cultures were incubated in a 
37°C shaker at a speed of 200 rpm overnight. On the second day, the 100-jiL starter culture 
was then transferred to a bigger culture sets containing 900 \iL SB in each well. The SB 
broth contained Vitamin B1 (20 |ig/mL) and lx KPB to improve the growth of small size 
culture. Cultures were grown to ODeoo of 0.5 before induction. 
LB broth 
The E.coli culture was grown in LB broth under similar conditions as above. Starter 
culture was grown overnight at 37°C with 100 LB medium containing 100 ng/mL of 
ampicillin, 15 jog/mL kanamycin and 2% (w/v) glucose. The next day, each clone of a 96-
clone set was grown in 900 mL LB medium 100 ng/mL of ampicillin, 15 ng/mL 
kanamycin and 20 ng/mL vitamin B1 at 37°C for 3 hours to a OD600 of 0.5 in 96 deep-well 
plate microplates (UNIPLATE, Whatman®) at 200 rpm before induction. 
Table 1. Ingredients of broth used for E.coli culture in this project. 
Broth / Ingredients 
Reagent 
LB 1.0 % (w/v) BactoTryptone, 0.5 % (w/v) yeast extract, 1.0 % (w/v) NaCl, pH7.4 
2YT 1.6 % (w/v) BactoTryptone, 1.0 % (w/v) yeast extract, 0.5 % (w/v) NaCl, pH 7.4 
SB 1.2 % (w/v) BactoTryptone, 2.4 % (w/v) yeast extract, 0.4 % (v/v) Glycerol 
lx KPB 4.6 % KH2P04,24.3 % K2HP04 
Induction 
All clones were induced with IPTG at final concentration of 1 mM at 37°C for 6 
hours. 
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Cell lysis 
After induction, bacterial cell pellets were collected by spinning the deep-well plate 
at 3000xg for 10 minutes (Beckman Coulter®). Cells were lysed for 5 cycles of complete 
freezing and thawing. The lysed cells were then subjected to immunoblotting. 
2) Western blots 
Lysed cells were transferred to a piece of nitrocellulose membrane using a 96 Solid 
Pin Multi-Blot Replicator (408, V&P Scientific). Western blot described previously was 
performed to visualize the presence of His-tagged proteins in the cell lysate. 
2.2.2 HTS induction optimization 
A 96 Solid Pin Multi-Blot Replicator (VP408, V&P Scientific, San Diego, CA) was 
used to transfer and inoculate 96 bacteria at a time. It is capable of inoculating 4 sets of 
clones from one 384-well stock plate. Prior to every application, metal tips of the replicator 
were dipped briefly in a 10% bleach solution, then into a series of two autoclaved milliQ 
water baths, followed by a 99% isopropanol bath. Between baths, the liquid on the pin tips 
was removed by light tapping on a piece of lint-free blotting paper (VP522, V&P Scientific, 
San Diego, CA). The pins were then air dried. In addition to the sterilization steps, pins 
were washed with wash buffer provided (V&P Scientific, San Diego, CA). 
An induction test was performed by comparing expression of the same set of clones 
induced under two different conditions: incubation for 16 hours at 16 °C and 6 hours at 
37°C. Proteins expressed under these two sets of conditions were purified. Four elutions 
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were collected and concentrations of proteins in each elution were compared to determine 
the best condition for small culture parallel purification. 
2.2.3 Methods to lyse bacterial cells for use in HTS and individual cell growth 
A 150 mL E.coli culture of clone F20568 was divided into three parts. Cell pellets 
from 50 mL cell cultures were each resuspended in 4 mL NPI-10 followed by the following 
lysis methods: 
1) Enzymatic method - cells were incubated in a final concentration of 1 mg/mL 
lysozyme for 1 hour; 
2) Sonication method - resuspended cells were sonicated 5 times at setting 4 (Fishers 
Scientific Sonic dismembrator Model 100) for 10 seconds each, with 1 minute time 
period on ice in between each sonication; 
3) Freeze and thaw method - the resuspended cells underwent 5 cycles of freezing on dry 
ice for 5 minutes and thawing in 37°C water bath for 3 minutes. 
SDS-PAGE 
Two 12% polyacrylamide gels were typically made together. Resolving gels were 
made by mixing 3.33 mL 30% acrylamide/0.8% bisacrylamide, 2 mL of 4x lower gel 
buffer (pH8.8), 2.67 mL of autoclaved water and 16 |*L of 20% ammonium persulfate 
(APS), and 4.8 jiL of TEMED (Sigma) and pouring into a gel apparatus (Biorad, Hercules, 
CA) at about 2/3 full immediately after mixing. The rest of the space was filled with water 
to flatten the top surface of the stacking gel. The water was removed after 30 minutes. The 
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5% SDS-PAGE stacking gel was made by mixing 0.48 mL 30% (w/v) acrylamide/0.8% 
(w/v)bisacrylamide, 0.75 mL of 4x lower gel buffer (pH 6.9), 1.77 mL of autoclaved water 
and 7.5 (iL 20% (w/v) ammonium persulfate (APS), and 3 faL of TEMED (Sigma) and 
quickly pouring it on top of the resolving gel after mixing. 
Before loading to the SDS-PAGE, each protein sample was processed by adding 16 
\iL to 4 (iL of 5x Sample buffer with 5 % (v/v) of p-mercaptoethanol. Mixed samples were 
then heated in boiling water for 5 minutes. As a reference, 5-10 |iL of molecular weight 
markers (Bio Basic, Inc., Markham, ON) was loaded to each gel. Gels with loaded samples 
were then run in lx running buffer at 200V for about 35 minutes until the bromophenol 
blue dye reached the edge of the gel. 
Table 2. List of reagents used in SDS-PAGE. 
Reagents Ingredients 
4 x Lower Gel Buffer 1.15 M Tris-HCl, 0.4% SDS, pH 8.8 
4 x Upper Gel Buffer 0.38 M Tris-HCl, 0.4% SDS, pH 6.9 
5 x Sample Buffer 249.75 mM Tris-HCl, pH6.8,10% SDS, 30% glycerol, 
0.012% bromophenol blue 
lx Running Buffer 20 mM Tris-HCl, 0.1 % SDS, 0.2 M Glycine 
Coomassie brilliant blue 50 % methanol, 10% acetic acid, 0.1% Coomassie brilliant 
blue R-250 
Destain Buffer 20% methanol, 10% glacial acetic acid 
2.2.4 HTS purification optimization 
Unclarified cell lysates were directly applied to a 96 unit HTS parallel His-tag 
recombinant protein purification system (His MultiTrap™ HP, GE Healthcare). The system 
was preloaded with 500 \iL of 10% highly cross-linked spherical agarose, precharged with 
Ni2+ ions (GE Healthcare). Prior to adding the lysates, His MultiTrap™ HP filter plates 
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were spun down at 500 x g for 2 minutes to remove the storage solution from the matrices. 
Five hundred microlitres of autoclaved milliQ water were then added, followed by two 
rinses with 500 \iL binding buffer containing 20 mM imidazole at 500 x g for 2 minutes 
each. The unclarified cell lysates were incubated with the matrices for at least 3 minutes, 
followed by centrifugation for 4 minutes at 100 x g. Unbound proteins were removed by 
adding 500 nL of wash buffer containing 40 mM imidazole and spinning down at 500 x g 
for 2 minutes twice. His-tagged recombinant proteins were eluted out in a 96-well 
collection plate (Corning) by adding 50 \x.h of elution buffer containing 500 mM imidazole 
to each well and mixing for 1 minute, and were subsequently spun down at 500 x g for 2 
minutes. Components of buffers required for the HTS protein purification are listed in 
Table 3. 
Table 3. Reagents used in HTS protein generation. 
Reagents Ingredients 
HTS lysis buffer 20 ng/mL DNase I, 1 mM MgC12, 1 mM PMSF, 20 mM 
sodium phosphate, 500 mM NaCl, 20 mM imidazole, pH 7.4 
HTS binding buffer 20 mM sodium phosphate, 500 mM NaCl, 20 mM imidazole, 
pH 7.4 
HTS elution buffer 20 mM sodium phosphate, 500 mM NaCl, 500 mM 
imidazole, pH 7.4 
1) Quantification of purified proteins 
Concentrations of protein samples were tested using the Bradford protein assay. 
The Dye Reagent Concentrate was diluted 5 times with distilled, deionized (DDI) water 
and filtered through a Whatman #1 filter paper. Duplicates of 9 dilutions of BSA (Thermo 
Fisher Scientific Inc., Waltham, MA) protein standard (0.03125, 0.0625,0.125, 0.25, 0.5, 
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0.75, 1,1.5 and 2mg/mL) and a blank (DDI water) were used to generate the standard 
curve. Ten microlitres of each protein from the original collection plate were added to a 
clear 96-well tissue culture plate. Two hundred fiL of the reagent was then added to each 
well of the microtiter plate. The microtiter plate with a mixture of the purified protein 
sample and reagent was gently shaken for a better mixing and left at room temperature for 
about 5 minutes to allow the colour to develop. Absorbance of the colour was then 
measured in a spectrophotometer (Multiskan, Thermo Scientific) at 600nm. 
2) Immunodetection of His-tagged recombinant proteins 
Western blots were performed to visualize the presence of His-tagged recombinant 
proteins before and after the purification. A multi-pipettor was used to transfer 1 jiL of 
each purified protein from the 96-well storage plate to a piece of nitrocellulose membrane 
with the same order as in the 96-well storage plate. The nitrocellulose membrane was 
allowed to dry on the bench before putting in lx TBS buffer containing lOmM Tris-HCl 
(pH 7.4), 0.15 M NaCl and 5% (w/v) skim milk for blocking overnight at 4°C. Following 
the blocking step, the membrane was incubated with 1° antibody (monoclonal anti-His 
antibody raised in rabbit, Affinity Bio Reagents, Golden, CO) diluted to 1/1000 in TBST 
buffer containing lOmM Tris-HCl (pH 7.4), 0.15 M NaCl, 0.1% (v/v) Tween 20 and 1% 
skim milk for 1 hour at room temperature. The membrane was quickly rinsed once with 20 
mL of TBST buffer immediately after the incubation. Each of three additional washes with 
the same buffer was done at room temperature for 10 minutes. The membrane was then 
incubated with 2° antibody (anti-rabbit, Promega, Madison, WI) diluted to 1/2000 in TBST 
with 1% skim milk for 1 hour at room temperature. After the incubation, the membrane 
was then washed three times as described previously. Blot detection was developed by 
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incubating the membrane with SuperSignal West Pico Chemilluminescent substrate (Pierce, 
Rockford, IL) for 1 minute and visualized under Chemlmager (Alpha Innotech, San 
Leandro, CA). 
2.2.5 HTS Dialysis Optimization 
Endoribonucleolytic activity of APE1 (44 ng) was shown to be inhibited in the 
presence of 500 mM imidazole (Oh, 2010). In two separate studies (Lunts 1976; Wolff 
1993) imidazole is also found to inhibit various enzymatic activities, and that a thorough 
dialysis step to exchange the buffer content is therefore necessary. 
To successfully exchange the buffer content using HTS micro-dialysis, we first 
need to develop a method to quickly determine the imidazole concentration and the time 
required for dialysis, and estimate the potential protein loss. 
(i) Using Nanodrop® spectrophotometer to estimate imidazole concentration 
A method of using wavelength spectrum peak position to estimate approximate 
concentration of imidazole present in a solution was discovered unexpectedly during the 
measurement of protein concentration using the Nanodrop spectrophotometer. Samples 
with different concentrations of imidazole in elution buffer were tested. The positions of 
absorbance peak on the wavelength spectrum were measured as a function of imidazole 
concentration. This test was repeated twice. 
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(ii) Minimum time required to remove imidazole using dialysis 
Minimum time required to remove imidazole from the protein solution was 
assessed. We used different sample volume sizes (50, 100 and 200 (iL) and tested with and 
without the presence of 1 mg/mL of bovine serum albumin (BSA) to assess how these two 
factors affect the dialysis speed. 
(iii) Test for protein loss during dialysis 
Pre-dialysis and post-dialysis concentrations of 0.5 mg/mL BSA and purified 
recombinant proteins were measured to determine the possible protein loss during dialysis. 
2.3 Results and discussions 
2.3.1 Comparison of protein expression in LB and SB 
To test whether there are any major differences in protein expression using the 
commonly employed LB broth and the special broths, 2YT and SB (2YT/SB), the same set 
of bacterial clones were grown in these media. Using Western blots to detect the presence 
of His-tagged proteins in E.coli grown in LB and 2YT/SB ( Figure 4), we found that most 
of the proteins in LB-grown cells were also detectable in 2YT/SB-grown cells. Although 
some dots were comparatively more intense in cells grown in LB, in general there were no 
major differences in protein expression in cells grown using these two different broths. 
Since this test was done after all five sets of clones had been purified, and LB 
medium is more convenient and common to use in the lab, it was later used as the growth 
medium for larger cultures, where special broth 2YT/SB were not necessary. Due to the 
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fact that this test was done after the high-throughput purification of several sets of clones 
was already performed, 2YT/SB were used continuously for all clone sets so as to keep the 
experimental conditions consistent. When growing bigger cultures at the post-screening 
stage, LB broth was used as it was suitable for growing higher volume of culture. 
1 2 3 4 5 6 7 8 9  1 0  1 1  1 2  1 2 3 4 5 6 7 8 9  1 0  1 1  1 2  
Figure 4. Western blots showing the expression of His-tagged proteins in the cells 
grown in different media. A) LB and B) 2YT/SB. More than 80% of clones show 
apparent expression of His-tagged proteins. No major differences in expression were found 
using these two sets of broths. 
2.3.2 Optimizing HTS bacterial induction step 
The average concentration of each elution (elution 1 - 4) and the total average of all 
elutions are shown in Table 4. Within all elutions, the 16-hour induction at 16°C appeared 
to produce a higher average of protein concentration. Elution 2 of both induction methods 
had a higher average protein concentration amongst all elutions. Not all of the proteins 
induced for 16 hours at 16°C had a higher concentration than the 6-hour induction at 37°C. 
Most of the clones produced higher protein concentration after 16 hours of induction at 
16°C. Another advantage of inducing proteins at a lower temperature and longer time is 
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that it allowed a higher chance of proper folding of proteins. Hence, all clones in this 
project were induced at 16°C for 16 hours. 
Table 4. Purified protein yields comparison of proteins induced with IPTG for 6 
hours at 37°C and 16 hours at 16°C. 
Average concentration of clone set S17A (mg/mL) 
Condition Elution 1 Elution 2 Elution 3 Elution 4 
6 hours @ 37 °C 0.184 0.231 0.050 0.100 
16 hours @ 16 °C 0.236 0.346 0.077 0.126 
2.3.3 Choice of cell lysis method 
Amongst the three cell lysis methods tested, the enzymatic lysis method might be 
the least vigorous for purifying recombinant proteins. However, when compared with the 
other two physical cell lysis methods, the protein yield was much lower. Between the two 
physical cell lysis methods, sonication was the most effective in lysing the E.coli cells as 
shown by the abundant target protein bands on the SDS-PAGE gel (Figure 5C, Lane 7). 
Despite its cell lysis effectiveness, the target protein produced under this cell lysis method 
also appeared to have a lower protein purity. As shown in Figure 5C, unwanted protein 
bands with various sizes are present in Elution 2. Another reason for the unsuitability of 
lysing cells using sonication is that some proteins may be sensitive to the vigorous 
vibration, and hence may be denatured. Taken together, the freezing and thawing method 
of lysing cells was the best cell lysis method. This method produced sufficient yields and 
was considered gentle. 
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Figure 5. SDS-PAGEs showing different fractions of 568F20 in the purification 
process after cell lysis with three different methods. A) Enzymatic cell lysis; B) Physical 
cell lysis using 5 freeze and thaw cycles; C) Physical cell lysis using sonication. A small 
size band shown in Part (A) indicates the presence of lysozyme in clear lysate, flow 
through and wash 1. The protein concentrations of elution 2 were estimated with NanoDrop 
Spectrophotometer. 
2.3.4 Optimizing HTS protein purification step 
To determine whether all clones produced similar His-tagged protein yield, an anti-
His-tagged immunoblotting was performed using cell lysates and post-dialysis protein 
samples. The Western blots show the corresponding His-tagged proteins were present in all 
cell lysate of set 517A (Figure 6A), but not all were present after purification (Figure 6B). 
38 
CH 2 DEVELOPMENT OF A HIGH-THROUGHPUT SYSTEM 
This might due to the proteins being in inclusion bodies and therefore not purified under 
native conditions. 
A B 
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Figure 6. Western blots showing His-tagged proteins from set 517A in cell lysate and 
after dialysis. One microlitre of each protein sample was transferred to the nitrocellulose 
membrane. (A) All of these clones show expression of His-tagged recombinant protein. (B) 
Only 34 out of 56 clones were able to produce detectable amount of purified recombinant 
protein. Data is adapted from unpublished report (Oh 2009). 
2.3.5 Using Nanodrop spectrophotometer to estimate imidazole concentration 
While measuring protein concentration using the spectrum peak position of a 
Nanodrop spectrophotometer wavelength, we discovered a method to assess the 
concentration of imidazole present in the solution. The absorbance peak's positions on the 
wavelength spectrum were measured as a function of the imidazole concentration. This test 
was repeated twice. 
The results show that the shift of the absorbance peak's position was consistent 
with the increased imidazole concentration (see Figure 7). According to this standard curve, 
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the concentration of imidazole can be estimated. For example, if the peak is located at 
around 228nm, imidazole in the solution would be approximately 0.5 M. Identical data 
from duplicated readings demonstrated the reliability of this method in estimating the 
imidazole concentration. This quick detection method using NanoDrop spectrophotometer 
allowed us to measure the concentration of imidazole and assess the effect of dialysis on 
imidazole concentration in the original buffer. 
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Figure 7. Position of absorbance peak shifting to the right on wavelength spectrum 
(increasing in wavelength) as imidazole concentration in the sample increases. 
2.3.6 Assessing the minimum time required for dialysis 
Figure 8 shows the effect of dialysis on the concentration of the imidazole, with and 
without BSA. In both conditions, the imidazole concentration dropped significantly after 
30 minutes, and remained constant after 120 minutes of constant buffer exchange with all 
sample volumes. Smaller sample volumes tend to have better chances of removing 
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imidazole from the buffer as indicated by a lower imidazole concentration of all time points. 
Hence, 50 |il dialysis sample size and 120 minute dialysis time were chosen for the HTS 
dialysis system. 
Another phenomenon was observed during the experiment. When the protein 
concentration was increased, the detected concentration of imidazole using the NanoDrop 
method was also increased at the same time. Two explanations are possible for this 
observation. First, the BSA proteins were partially blocking the membrane and 
subsequently decreasing the exchanging rate of buffers. Second, the presence of BSA was 
interfering with the absorbance measurement. This could be due to the similarity of ring 
structures present in both imidazole and some amino acids such as histidine. 
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Figure 8. Determining the time required to decrease imidazole concentration during 
dialysis. (A) Test run using 0 mg/ mL BSA; (B) Test run using 1 mg/mL BSA. 
41 
CH 2 DEVELOPMENT OF A HIGH-THROUGHPUT SYSTEM 
2.3.7 Determining the amount of protein loss during dialysis 
We anticipated that certain amounts of protein loss may occur during dialysis. Two 
trials were run using 96 BSA samples and 36 recombinant proteins from set 517A 
respectively. The concentration was estimated by Bradford protein assay. Concentrations of 
BSA after dialysis were very similar to their pre-dialysis concentration of 0.5 mg/mL. The 
average concentration of BSA after dialysis was 0.554 mg/mL, with a low standard 
deviation of 0.038. Hence, the dialysis had not caused any significant protein loss in the 
BSA samples. 
Table 5. Purified protein sample concentrations (mg/mL) of before (A) and after (B) 
dialysis, and percentage (%) decrease of concentration (C). Clones tested were from 
rows K, M and O, and columns 1,3,5,7,9,11,13,15,17,19, 21 and 23 of plate 517. 
A 
1 3 5 7 9 11 13 15 17 19 21 23 
K 0.112 0.113 0.111 0.071 0.071 0.087 0.023 0.094 0.090 0.140 0.131 0.006 
M 0.126 0.166 0.141 0.204 0.140 0.117 0.114 0.126 0.155 0.085 0.105 0.003 
0 0.077 0.173 0.170 0.095 0.150 0.099 0.138 0.117 0.098 0.132 0.097 0.039 
B 
1 3 5 7 9 11 13 15 17 19 21 23 
K 0.037 0.050 0.043 0.033 0.038 0.045 0.028 0.077 0.061 0.104 0.079 0.020 
M 0.066 0.105 0.064 0.094 0.079 0.057 0.049 0.050 0.061 0.041 0.053 0.001 
O 0.042 0.086 0.081 0.045 0.073 0.053 0.084 0.062 0.049 0.068 0.051 0.049 
c 
1 3 5 7 9 11 13 15 17 19 21 23 
K 66.9 55.9 61.2 53.9 47.0 48.1 -21.7 17.7 32.6 25.6 39.4 -258.7 
M 47.7 36.6 54.7 54.1 43.4 51.4 56.9 60.1 60.4 51.3 49.8 56.2 
0 45.4 50.6 52.3 52.8 51.0 46.2 38.9 46.7 49.7 48.3 47.0 -26.2 
In contrast, the 2 hour dialysis seemed to have a significant effect on the 
concentration of the recombinant proteins. The majority of the protein concentration 
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dropped after dialysis in comparison to their pre- and post-dialysis concentrations (Table 5, 
panel A & B). The average concentration of purified proteins before dialysis was 0.109 
mg/mL with a maximum of 0.204 mg/mL and a minimum of 0.003 mg/mL. The average 
concentration of purified proteins after dialysis was 0.058 mg/mL, with a maximum of 
0.105 mg/mL and a minimum of 0.001 mg/mL. The average percentage decrease in 
concentration was 35.9%, with a maximum of 66.9% and a minimum of -258.7%. As 
observed in Table 5C, the concentrations dropped uniformly for most of the clone after 
dialysis with the exceptions of clones K13, K23, and 023. This may be due to the different 
size of each clone. As compared to most of these clones, BSA is relatively bigger, with the 
size of about 68 kDa. In summary, concentration of recombinant protein is expected to 
decrease about half after dialysis. 
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High-Throughput Functional Screen 
3.1 Introduction 
The real-time fluorescence-based assay previously developed in Dr. Lee's lab has 
been shown to be valid for the measurement of endoribonuclease activity of APEl (Kim et 
al. 2010). The principle of this method is based on the signal of a fluorophore attached to 
5'- end of the substrate (Figure 9). Increase in fluorescence signal subsequently occurs 
upon cleavage of the substrate and separation of the fluorophore from the quencher. The 
signal is picked up by the fluorescence multiplate reader (Varioskan Flash Multimode 
Reader, Thermo Scientific). Similar fluorescence-based assay has been conducted, 
supporting the effectiveness of this method in accessing ribonuclease activity (Wang and 
Hergenrother 2007). 
ENdoRNase 
(SO 
BHQ1 — Cy3 C BHQ1 
'/# IWN 
Figure 9. Principle of fluorescence-based assay used in high-throughput screen. The 
left hand side of the figure shows fluorescence signal of fluorophore Cy3 being quenched 
by the nearby quencher BHQ1 when the substrate is uncleaved. The right hand side of the 
figure shows an enzymatic reaction with the presence of endoribonuclease causing 
separation of BHQ1 from Cy3 and hence dequenching. 
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3.2 Methodology 
3.2.1 HTS 96 parallel protein expression and purification 
1) HTS small culture production 
Inoculation 
Two special media, 2YT and SB, with 100 |ig/mL of ampicillin and 15 |ig/mL 
kanamycin, were used according to the recommended conditions for small size culture 
(Lueking, 1999; Bussow, 1998). Two percent (w/v) glucose was added to 2YT and 20 
Hg/mL vitamin B1 and lx KPB was added to SB to ensure the healthy growth of small size 
cultures. 
The ingredients in these two broths are listed in Table 1. A 96-well plate was used 
to grow the starter culture. The starter culture of each clone was incubated in two sets of 
100 (iL 2YT overnight in a 37°C shaker at a speed of 200 rpm. On the second day, 100 jxL 
starter culture was transferred to each of the two bigger culture sets containing 900 jiL SB 
in each well. 
Bacterial culture 
For sets 517A, 523C, 525A and 568D, clones were grown in two 96-well deep 
microplates (UNIPLATE, Whatman) new cultures by incubating for 3 hours to the ODeoo 
of 0.5 before induction. To evaluate the possible advantage of using higher culture volume, 
set 512A was grown in four 96-well deep microplates instead of two. A final concentration 
of ImM IPTG was put into the culture to induce the recombinant protein expression. 
Bacterial cell pellets were collected by spinning the deep-well plate at 3000 x g for 10 
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minutes (Beckman Coulter). Pellets were stored in capped deep-well plate at -80°C until 
the cell lysis step. 
2) HTS parallel cell lysis 
Mechanical cell lysis method was used to lyse all cells simultaneously. Cell pellets 
were re-suspended in 250 }iL HTS lysis buffer using a multichannel pipettor (Fisher). Re-
suspended cell pellets of the same clones were combined in one plate, followed by a series 
of at least five freezing and thawing cycles done at - 80°C and 37 °C respectively. 
Unclarified cell lysates were produced after the cell lysis. 
3) HTS recombinant protein purification 
Recombinant proteins were purified as described in Chapter 2. Typically, 4 
fractions were collected for each purification procedure. Purified His-tagged proteins were 
then subjected to dialysis or kept at -80°C until proceeding to dialysis. 
3.2.2 HTS dialysis and quantification 
1) HTS dialysis 
All second elution fractions were subjected to dialysis using a 96-well 
microdialyzer (Spectra/Por) to exchange a buffer for 96 proteins at a time. In this process, 
500 mL of dialysis buffer, with a pH of 7.4, contained 50 mM of Tris and 10 mM of MgCl2 
was used. For two hours the buffer was continuously exchanged from one buffer chamber 
via a tube to a lower buffer chamber. The dialyzed proteins were then stored in another 
new sterile collection plate and stored at -80°C. 
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2) Quantification of dialyzed proteins 
The concentrations of protein samples were measured by performing the BioRad 
protein assay as described in Chapter 2. 
3.2.3 HTS protein functional screen 
To identify candidate recombinant proteins capable of cleaving miR155, a dual 
labeled substrate was synthesized based on the mature form of miR155 (Figure 10). It was 
attached with a fluorophore (Cy3) and a quencher (BHQ1) to the 5'- and 3'- end, 
respectively (IDT, Coralville, IA). Screening results using the miR155 substrate were 
compared with Oligo CG, CU, and UA as controls to detect sequence specific 
endoribonuclease activity. The predicted secondary structures of these control 
oligonucleotides are shown in Figure 11. The sequence of each substrate is shown in Table 
6. 
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Figure 10. Secondary structure of the miR155 substrate used in the fluorescence-
based assay, which was designed based on one of the mature miR155 secondary 
structures. (A) miR155 substrate; (B) mature miR155. RNA structures were predicted by 
Mfold RNA folding program. 
BHQ1 
Figure 11. Secondary structures of substrates used as controls. Structures were 
predicted by Mfold RNA folding program. (A) Oligo UA; (B) Oligo CG; (C) Oligo CU. 
The prefix "r" denotes ribonucleotide. The rest of the substrate is composed of 
deoxiribonucleotides. 
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Table 6. List of substrates used in the fluorescence-based assay and their sequences. 
Substrate Sequence* 
miR155 Cy3 - 5'-rCrUrArArUrCrGrUrGrArUrArG-3' - BHQ1 
Oligo UA Cy3 - 5'-C AAGGTAGTrUATCCTTG-3' - BHQ1 
Oligo CG Cy3 - 5 '-C AAGGT AGTrCGTCCTTG-3' - BHQ1 
Oligo CU Cy3 - 5'-CAAGGTAGTrCrUTCCTTG-3' - BHQ1 
Note: * The prefix "r" denotes ribonucleotide. 
A total of480 clones from 5 unbiasly selected sets (512A, 517A, 523C, 525A and 
568D) were tested for the validation of the HTS screening test. A fluorescence-based assay 
was performed to screen for positive hits from the candidate pool of these 480 clones. 
The fluorescence-based assay contained 20 nM of the miR155 substrate (Figure 10 
A) and 5^L of protein in a total volume of 80 [iL containing 50mM Tris and 2 mM MgCk 
at pH 7.4. The fluorophore was excited at a wavelength of 533 nm and fluorescence is 
absorbed at 563 nm every 30 seconds for 30 cycles. The RFU readings were measured over 
a time period of 15 minutes. RNase A cleaves specifically at the 3'side of U and C on both 
single and double strand RNA (delCardayre et al. 1995) and was therefore used as a 
positive control. DEPC-treated water was used as negative control. Ingredients of each 
fluometric assay reaction are shown in Table 7. 
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Table 7. Components in fluorescence-based assay reaction. 
Content Final amount/concentration 
in reaction 
Volume (}iL) 
miR155 substrate 
Protein 
Reaction Buffer (pH7.4) 
Positive control (RNase A) 
Negative control 
(DEPC-treated Water) 
20 nM 
Various (0-3.37 mg) 
Tris 50 mM 
MgC12 2 mM 
0.01 ng 
Not applicable 
1 
5 
74 
1 
1 
3.3 Results and discussions 
3.3.1 Protein concentrations 
The average concentration of all sets as measured by the Bradford method was 0.06 
mg/mL; the lowest concentration was 0 mg/mL, and the highest concentration was 0.674 
mg/mL. Set 512A had a higher average concentration (0.1 mg/mL) because clones from 
this set were grown in four 96-well plates with a total of 4 mL culture for each clone, 
instead of two plates for the rest of the sets. 
3.3.2 HTS fluorescence-based assay 
There are five possible ways to select positive hits from the above screens: 1) 
"Manual selection" picks up clones that stand out and created an obvious increase of RFU 
as a function of time; 2) "Last RFU method" uses the value of last RFU as criteria of 
selection; the higher the last RFU, the stronger the signal; 3) "Last RFU normalized to the 
protein concentration" method uses the value of last RFU divided by the concentration of 
the respective clone to detect enzymatic activity; 4) "Percentage change method" measures 
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the percentage change from the first RFU to the last RFU, the higher the percentage change, 
the stronger the signal; 5) "Percentage change normalized to the protein concentration" 
method uses the RFU percentage change of a clone from method 4 over its own 
concentration. 
The manual method (method 1) was the fastest amongst all the five methods as it 
did not require calculations, sorting and normalization of the data. However, using merely 
visualization to select positive hits may increase the risk of missing some true positives. 
Moreover, RFUs in all wells increased in some screens. This is one of the reasons why 
using method 1 is not feasible, because if the maximum RFU value is very high within the 
run (as obtained with the positive control RNase A), the baseline is pushed down to the 
bottom of the graph and tends to look flatter. The increase of the RFU is less observable in 
this case therefore some positive hits may be missed using this method. 
Method 4 and 5 were not used for a technical reason. The reaction captured in a 
graph may vary depending on the activity of the enzymes. Two hypothetical fluorescence 
signal curves representing two activity levels are shown in Figure 12. Time point "a" and 
"b" represent the first and last reading in fluorescence-based assay. Due to technical reason, 
there is often a gap between the zero time point and the first reading. When the RFU value 
of a strong enzyme such as RNase A already reaches a very high level at time point "a", a 
low percentage change in RFU is obtained and therefore would be missed in the screen. 
Hence, method 4 and 5 were not suitable for identifying very active enzymes. 
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Figure 12. Kinetics curves of enzymes of diffferent activities. RFUs from time points "a" 
to "b" are representing the relative fluorescence units capture in one fluorescence-based 
assay. RFU at time point "b" is a better representation of the activity strength than the 
percentage RFU increase from "a" to "b". 
Method 3 and 5, both using the protein concentrations to normalize the fluorescence 
signals, can be problematic as some of the clones had produced very small amounts of 
proteins. If these small values were used to normalize the RFU values obtained in the 
fluorescence assay, these candidate proteins would be erroneously identified as having 
strong enzyme activity. Furthermore, as demonstrated in Figure 12, last RFU is more 
suitable in representing the signal strength. Because of the above reasons, method 2 using 
the last RFU was selected to identify candidates for further analysis. Using this method, 
clones were categorized into 3 groups based on their activity: high, low or negative. Clones 
that belong to the "high" activity group are clones with the last RFU higher than two 
standard deviations above the average RFU for the clone set. Clones that have "medium" 
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activity have their last RFU higher than one standard deviation above the average RFU. 
The rest of the clones are considered to be negative. 
A representative primary fluorescence screen for a set of 96 clones (517A) is shown 
in Figure 13. Using the last RFU method, clones with high and medium activity were 
identified and indicated by H and M respectively. The top ten clones that produced the 
highest amount of protein are indicated by an asterisk (*). It is worth noting that these 
clones did not necessarily produce high signals in the assay. As exemplified in this set of 
data, most of the positive hits (either H or M) appear to be cleaving both the miR155 and 
Oligo UA substrate (e.g. A17 and C07). It is interesting to note that the RFU value 
obtained for RNase A in the assay are often decreasing with time during the measured time 
period due to fluorescence bleaching. 
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Figure 13. Representative results of fluorescence-based assay to screen for activity 
against the miR155 substrate and Oligo UA. (A) Screen against miR155; (B) screen 
against Oligo UA. Each square represents the RFU signals plotted as a function of time in a 
15-minute time period after the addition of the respective substrates to proteins purified 
from the clone set 517A. All RFU values presented were normalized to the maximum value 
obtained with 5 jig of RNase A, which was included as a positive control (+) in each assay. 
DEPC-treated water was included in each assay as negative control (-). Reactions with "H" 
indicate ranking with high signal and reactions with "M" indicate ranking with medium 
signal as according to the ranking method used. The top ten high concentration clones are 
marked with an asterisk. High = last RFU > average RFU of each set +2x standard 
deviation; Medium = last RFU > average RFU of each set + 1 x standard deviation. 
Average RFU for the set was calculated using the last RFU values from all the clones 
except the clones that produced obviously high signal in the assay (eg. 119). 
The list of positive hits is longer than what we anticipated. Average rate of positive 
hit for one set was about 23 %. It is very possible that a considerable portion of these "hits" 
are false positives due to contamination. There are two hypothetical approaches to 
eliminate the false positive. The first approach is to compare the reproducibility of 
screening results. Screens of sets 517A, 525A and 568D were repeated at least one more 
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time. When the different screen was compared, only some hits were reproducible in both 
lists. As shown in Table 8, not all hits are reproducible and the number of reproducible 
positive hits only covered less than half of all hits from two combined trials. However, 
repetitive screen was not performed with sets 512A and 523C due to the insufficient 
amount of protein samples. Although this approach was not applied to all clone sets and 
hence was not used to eliminate false positive, we were aware of this problem. 
In the second approach used to eliminate the false positives we focused on hits that 
were positive only toward miR155 but not Oligo CG and CU or Oligo UA (Oh 2010; 
Woodbeck 2010). We reasoned this may be a suitable way to quickly eliminate false 
positives based on the possibility that some bacterial RNase may contaminate the protein 
samples. This method can also help us focus on clones that may possess substrate 
specificity toward miR155. A total of 25 positive candidates selected for all sets (Table 9) 
were subjected to further post-screening or secondary screen analysis. These clones 
appeared to be positive in at least one trial. 
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Table 8. Comparison of positive lists from two repeated screens (Trial 1 and 2). 
517A 525A 568D 
Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2 
A01 A01 A01 B04 
A05 A03 B06 
A07 A05 B08 
A17 A17 A09 A09 B16 
A21 A21 A15 A15 B18 
C07 A17 A17 B22 
C17 A19 A19 D18 
C19 C19 A21 D22 D22 
E17 C09 D24 
E19 E19 C15 C15 F06 
105 105 E01 F08 F08 
109 E15 E15 F20 F20 
119 119 E17 F22 
K07 E23 H02 
K17 G03 G03 H04 
M01 105 105 H06 
M17 115 115 H12 
005 123 123 H14 
019 019 M01 H18 
M09 H20 
Mil Mil H22 
M15 M15 J10 
M23 J16 J16 
001 J20 
L20 L20 
N10 
N12 N12 
N14 
N20 
N22 
P02 
P16 
P22 
Note: Reproducible positive hits are bolded and shown in both columns (e.g. A17 and A21 
in set 517A). In set 517A, 7 positive hits were reproducible; in set 525A, 13 positive hits 
were reproducible; in set 568D, 6 positive hits were reproducible.) 
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Table 9. List of clones exhibiting specificity toward miRISS substrate. 
Clone MPMGp800.. Signal Ranking * Reproducibility** 
C19512 Medium N/A 
E15512 Medium N/A 
123512 Medium N/A 
013512 Medium N/A 
023512 Medium N/A 
A01517 Medium N 
E17517 Medium N 
B01523 Medium N/A 
F01523 High N/A 
L01523 High N/A 
NO1523 High N/A 
P07523 Medium N/A 
P09523 High N/A 
A15525 High R 
CI5525 Medium R 
E15525 High R 
G03525 Medium R 
B06568 High N 
D24568 Medium N 
F06568 Medium N 
F20568 High R 
H06568 Medium N 
J10568 Medium N 
J16568 Medium R 
N10568 Medium N 
Note: * RFU signals in fluorescence assay: High = last RFU > average RFU of each set 
+2x standard deviation; Medium = last RFU > average RFU of each set + 1 x standard 
deviation. ** R- reproducible hit, N- not reproducible, N/A- data not available. 
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Post Screening Analysis of the Positive Hits 
4.1 Introduction 
4.1.1 Rationale for carrying out secondary screen 
Post screening analysis (secondary screen) is necessary because the positive hits 
obtained from the high-throughput screen (primary screen) might contain false positives, 
especially with such a high percentage of total positive hits (23%) initially identified in 
Chapter 3. Several factors may contribute to the occurrences of false positives. 
First, cross contamination amongst clones in 96-well plates during the bacterial 
growth is possible and can introduce a second recombinant protein into adjacent protein 
samples during the handling of clones in 96-well plates. In this case, an inactive clone can 
be contaminated with an adjacent active clone and be selected as a positive hit. Second, 
since the recombinant protein is grown in the E.coli cells, the bacterial host itself can be a 
source of contamination. Third, during the high-throughput cell lysis, a batch of DNase I 
(Roche, Switzerland) was added to the lysis buffer according to the manufacturer's 
protocol (Table 5). We later found out that this batch of DNase I powder contained RNase 
activity. The RFU was increased with the increased amount of this DNase I (data not 
shown). Although this contaminant may not remain with the purified protein, this finding 
cautioned us about the possibility of false positive signal in the screen when this batch of 
DNase I was included in the primary screen. Lastly, it was also possible that some of the 
positive hits selected were not endoribonucleases. Exoribonuclease and RNA binding 
protein could also alter the stem loop structure of miR155 substrate (Figure 10A) and 
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subsequently cause the Cy3 to be distant from BHQ1. Therefore, post screening analysis 
must involve electrophoretic assay which can distinguish these possibilities. 
4.1.2 Electrophoretic assay to characterize positive hits 
The fluorescence-based screen was designed for quick detection of potential 
ribonuclease activity, but it could not provide details of the activity. The electrophoretic 
assay was used to access the RNA cleaving activity and the RNA cleavage sites generated 
by candidate enzymes. Electrophoretic assays with four different substrates were carried 
out to further understand and characterize the possible enzymatic activity of the selected 
proteins. By radiolabeling the substrate at either end, the nature of the cleavage products 
can be determined when the substrate was cleaved. 
Two substrates were designed based on the mature miR155 sequences, and they 
differed by nucleotide length. The 13 nucleotide substrate (miR155_13nt, Figure 14A) was 
identical to the substrate sequence used in the screen, except that it had no fluorophore and 
quencher attached. As mentioned in Chapter 3, the 13-nt substrate was an artificial 
substrate derived from the mature form of miR155 and fits the technical criteria of 
fluorescence-based assay. After all, it is not the actual mature miR155 itself. Therefore, it is 
deemed important to include the second 24-nt full length (miR155_24nt) which more 
closely mimics the biological structure. The most stable predicted secondary structure of 
miR155_24nt is shown in Figure 14B. 
Substrate Oligo CU-aR (Figure 15) was used as a control for two reasons. First, it 
was used as a criterion to eliminate false positives in the screening step. Second, using a 
different substrate could provide more RNA cleavage information and possibly answer the 
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question as to whether enzymatic activity was sequence specific. The Oligo CU-aR 
substrate used in electrophoretic assay was composed entirely of ribonucleotides instead of 
the hybrid form used in the primary screen. The suffix "aR" indicates ribonucleotide 
composition in the substrate, distinguishing it from the fluorogenic substrate Oligo CU. To 
further determine whether the candidate enzyme possesses exoribonucleolytic activity, 
Poly (A) 15 substrate was used. 
To be consistant with the primary screen, RNase A was used as a positive control. 
Clone E01517 was include as a negative control, because it did not cleave miR155 in the 
primary screen and had a relatively high protein yield. 
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Figure 14. Secondary structures of electrophoretic assay substrates miR155_13nt and 
miR155_24nt. (A) Structure of short form substrate miR155_13nt; (B) structure of full 
length substrate miR155_24nt. These structures were predicted by mfold RNA folding 
program (Zuker 2003). The initial loop free energies dG are 2.2 kcal/mol and -0.1 kcal/mol 
for miRl 5513nt and miRl 55_24nt respectively. 
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Figure 15. Secondary structure of electrophoretic assay control substrate Oligo CU-
aR. This folding was predicted by mfold RNA folding program (Zuker 2003). The initial 
loop free energy dG is - 4.00 kcal/mol. 
4.2 Methodology 
4.2.1 Induction test of positive clones 
1) Individual clone production 
Two 50 mL cultures were grown for each positive candidate, one of which was 
induced by IPTG at 16°C for 16 hours, and another one without IPTG. Both were incubated 
until ODax) reached 0.5. After induction, cells were spun down after the induction and 2 
mL of cell lysis buffer was added into each tube to re-suspend the bacterial pellet. All tubes 
were subjected to at least 5 cycles of freezing on dry ice and thawing at 37°C to lyse the 
cells. Clear cell lysates were obtained after spinning the lysed cells at 3000xg for 20 
minutes. The uninduced control samples were subjected to identical procedures. 
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2) SDS-PAGE 
SDS-PAGE gels were made following the protocol described in Section 2.2.4. 
Sixteen- microlitres clear cell lysate were mixed with 4 |iL of 5x sample buffer containing 
5% of P-mercaptoethanol. Samples were then boiled at 95°C for 3 minutes prior to loading 
to a 12% gel. The SDS-PAGE was run at about 200 volts for 35 minutes or until the dye 
reached the bottom of the gel. The SDS-PAGE gel was then stained in Coomassie brilliant 
blue for 15 minutes and destained in destaining buffer for a minimum of 2 hours. Purity of 
the His-tagged protein was measured by the ratio the density of this protein to the density 
of the whole sample including background. 
4.2.2 Expression and purification of positive clones 
1) Individual recombinant protein purification 
Bacterial culture 
For each positive clone, 200 mL culture was typically grown in LB broth containing 
100 jig/mL Ampicillin and 25 ng/mL Kanamycin to an OD6oo of at least 0.5, and induced 
with 0.1 mM IPTG at 16°C for 16 hours. E.coli cells were collected by spinning at 3000xg 
for 25-30 minutes after induction; 4 mL of cell lysis buffer was added into each tube to 
resuspend the pellet. All tubes were subjected to at least 5 cycles of freezing on dry ice and 
thawing at 37°C to lyse the cells. Clear cell lysates were obtained after spinning the lysed 
cells at 3000xg for 20 minutes. To remove the cell debris, lysed cells were centrifuged in 
Eppendorf tubes at 10,000 xg for 20-30 minutes. 
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Gravity flow purification 
Four-mililitre clear cell lysate was then incubated with 2 mL of 50% Ni-NTA slurry 
(Qiagen, Valencia, CA) in a 15 mL capped column on an orbital shaker at 4°C for about 1 
hour. Resin with bound proteins was then washed twice with 4 mL wash buffer to remove 
proteins that unspecifically bound to the matrices. His-tagged proteins are then eluted out 
four times with 0.5 mL elution buffer in each elution. All flow-through fractions were 
collected for SDS-PAGE analysis purpose. 
During the preparation of Ni-NTA column, 2 mL of 50% precharged nicol resin Ni-
NTA (Qiagen, Valencia, CA) was rinsed twice with five volumes of autoclaved milliQ 
water and equilibrated by rinsing twice with five volumes of lysis buffer. Resins were used 
up to a maximum of five times before being discarded. 
The purification procedure described above was slightly modified from the Qiagen 
"The QIAexpressionist™" 6x His- tagged protein purification protocol. Contents of 
reagents used are described in Table 10. 
Table 10. List of reagents used in gravity flow purification. 
Reagents Ingredients 
Lysis buffer 50 mM NaEhPO^ 300 mM NaCl, 10 mM imidazole, pH 8.0 
Wash buffer 50 mM NaH2P04, 300 mM NaCl, 20 mM imidazole, pH 8.0 
Elution buffer 50 mM NaHhPO/i, 300 mM NaCl, 500 mM imidazole, pH 8.0 
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2) Dialysis 
To remove the high concentration of imidazole in the elution buffer, two 100-jiL 
protein samples from the elution with the highest concentration of protein were dialyzed 
with 50 mL of dialysis buffer containing 50mM Tris, 2 mM MgC12 and 20% (w/w) 
glycerol with pH of 7.4 for a total of five hours. Buffer was changed once after 2.5 hours of 
dialysis. After dialysis, proteins in exchanged dialysis buffer were then collected in 
individual Eppendorf tubes and stored at -80 °C. 
4.2.3 Secondary screen using fluorescence-based assay 
A secondary screen using fluorescence-based assay was performed to confirm the 
positive hits as found in the primary screen. Similar to the primary screen, each reaction 
contained a total volume of 80 jiL. One microgram of purified recombinant protein was 
added to the fluorescence assay buffer containing 20nM of the dual-labeled miR155 
substrate. RNase A (0.25ng) was used as a positive control; DEPC treated water (1 ^L), 
DNase I (2 U) and clone E01517 (1 |ig) were used as negative controls. 
4.2.4 Identity of Positive Hits 
1) Growing bacterial culture for plasmid extraction 
A 5 mL E.coli bacteria culture was grown in LB medium with 25 |xg/mL Ampicillin 
overnight at 37°C; the inoculation was done directly from the original 384 well plate by 
pipette tip picking. Bacterial cells were pelleted by spinning at 17,900 x g for 10 -15 
minutes and subjected to plasmid purification as per manufacturer's instruction. 
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2) Plasmid extraction 
The plasmids from relevant clones were extracted using QIAprep® Spin Miniprep 
Kit. Amounts of all buffers were doubled corresponding to the high copy of plasmid in the 
5 mL culture as recommended by the manufacturer's protocol. 
Cell pellet was first resuspended in 500 jiL Buffer PI with RNase A and then 
transferred to two Eppendorf tubes. Next, 250 \iL of Buffer P2 was added to each tube and 
mixed with the previous solution by inverting 6 times. Immediately after 350 (iL Buffer N3 
was added to the previous mixture, the tube was inverted 6 times for a thorough mix. Cell 
debris was then pelleted by spinning the tubes at 17,900 x g for 10 minutes. Supernatants 
from the previous spinning were then transfer to and spun through the QIAprep spin 
column (Qiagen, Valencia, CA) for 60 seconds each tube. 0.5 mL of Buffer PB was added 
to the spin column followed by washing of 0.75 mL Buffer PE to wash out unwanted 
residual. The spin column was spun at 17,900 x g for 60 seconds after each wash. An 
additional 1-minute spin was applied to remove excess wash buffer. The plasmid was 
eluted with 50 nL milliQ water by incubating for one minute and then centrifuging for 
another minute (Qiagen). 
Plasmids were then sent to MACROGEN (Seoul, Korea) for clone identification by 
DNA sequencing. Two universal primers, SP6 and T7, were first used for DNA sequencing. 
Identities of clones were determined using BLAST (National Center for Biotechnology 
Information). We later realized it was necessary to precisely determine the entire sequence 
of the clones. Although we were able to find protein matches using the sequencing results 
obtained using SP6 and T7, we could not determine whether the His tagged protein was in 
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frame since they were both located downstream of the 6xHis tag (Figure 3). Plasmids from 
the positive clones of first priority were then subjected to another round of DNA 
sequencing. 
The second round of DNA sequencing was performed using two different primers 
(pQE-F and pQE-Nhel-R) to determine the entire sequence and to check whether the 
cDNA inserts were in frame as pQE-F anneals to a location upstream of the His-tag. 
Sequences of all four primers used in DNA sequencing are shown in Table 11. 
Table 11. List of primers and their sequences used in cDNA sequencing. 
Primers Sequence 
SP6 5'-ATTTAGGTGACACTATAG-3' 
T7 5 '-T A AT ACGACTC ACT AT AGGG-3' 
pQE-F 5-CCCGAAAAGTGCCACCTG-3' 
pQE-Nhel-R 5-CAAGCTAGCTTGGATTCT-3' 
4.2.5 Dephosphorylation of miR155 substrates (13nt and 24 nt) for use in 
electrophoretic assay 
MiR155_13nt and miR155_24nt oligonucleotides were both dephosphorylated at 
the 5' end by the same procedure. The substrates were incubated in 37°C for 1 hour with a 
final concentration of 15.6 pmol/p.L. The 80 p.L reaction mixture contained 1 |iL of 40 U/ 
jiL RNasin® (Promega, Madison, WI), 1 of 2 U/ ^L Calf Intestine Phosphatase/CIP 
(New England Biolabs, Beverly, MA), 8 fi,L of lOx NEBuffer 3 (New England Biolabs, 
Beverly, MA), 1 nL of 10 nM DTT (Promega, Madison, WI). The rest of the volume was 
adjusted with DEPC treated water. The reaction was stopped by adding 20 |iL of 10% SDS, 
4 nL of 5M NaCl, 1 \ih of 0.5 M EDTA (pH8.0), and 120 jiL of DEPC treated water. 
66 
CH 4 POST SCREENING ANALYSIS 
Following the dephosphorylation, the substrates were subjected to the standard 
phenol/chloroform extraction. 
4.2.6 Standard phenol/chloroform extraction and ethanol precipitation 
1) Phenol/Chloroform extraction 
DEPC-treated water was added to bring the volume of dephosphorylated substrate 
to 200 fiL. One hundred microlitres of phenol (100 ^L, pH 6.7, Sigma) and 100 |aL of 
chloroform:isoamylalcohol (CHCl3:IAA = 4:1, Fluka) were added to the sample and mixed 
by gentle inverting. The mixture was then centrifuged at 12,000 rpm for 5 minutes at 4°C. 
The aqueous layer was transferred to a new tube and the volume of it was estimated. One 
volume of chloroform:isoamylalcohol (CHC^IAA = 4:1, Fluka) was added to the tube and 
mixed by gentle inverting. The mixture was centrifuged at 12,000 rpm for 5 minutes. The 
aqueous layer was then transferred to another new tube. 
2) Ethanol precipitation 
Two volumes of 100% ethanol and 1/10 volume of lOx Glycogen (pH 5.2) were 
added to the tube. The tube was mixed well and left at -20 °C for at least 30 minutes. 
Precipitated RNA was then pelleted by spinning the tube at 12,000 rpm for 10 minutes. 
Supernatant was gently pipetted out from the tube. The pellet was then rinsed by adding 
200 (aL of 70% ethanol and spun down at 12,000 rpm for another 5 minutes. The pellet was 
dried by pipetting the ethanol out, left inside a running fume hood for 20 minutes, and 
resuspended by adding 30 \iL of DEPC treated water. All extracted dephosphorylated 
substrate was stored at -80°C. 
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4.2.7 Production of 5' radiolabeled substrates for use in electrophoretic assay 
1) 5' labeling reaction 
Concentrations of dephosphorylated RNA determined using the NanoDrop® 
Spectrophotometer (Thermo Scientific). Samples were diluted to 5pmol/|iL. A 12.5 jiL 
reaction mixture contained 2.5 |iL dephosphorylated RNA (5 pmol/ )iL), 1.25 \iL lOxPNK 
buffer, 1 p.L of 40 U/ RNasin® (Promega, Madison, WI), 1 (iL of 100 mM DTT 
(lOOmM) (Promega, Madison, WI), 1 (iL of 1U/ jiL T4 PNK, 3.8 \iL y-32P-ATP (10 jiCi/ 
nL/3.32 pmol, PerkinElmer Inc., Waltham, MA) and 1.95 \iL DEPC treated water. The 
reaction mixture was mixed and incubated at 37°C for 1 hour. The reaction was stopped by 
adding 15 p.L RNA stop dye in each tube. Labeled substrates were either kept at -20°C 
immediately or proceeded to gel purification step. 
2) Gel purification of radiolabeled substrate 
The 15% denaturing polyacrylamide gel was made by adding 48 mL pre-made 15% 
poly acrylamide containing 7M urea with 65 jiL of TEMED (N,N,N',N'-
tetramethylethylenediamine) and 180 (iL 20% APS, and poured to the thin space in 
between two assembled glass plates immediately after. A 17-comb spacer was used to 
create sample loading wells. The gel was left to solidify in room temperature for about 30 
minutes. 
After loaded into the 15% denaturing polyacrylamide gel, radiolabeled substrates 
were separated from any degraded fragments and excess free y- P-ATP by running at 25 
mAmp for 50 minutes. The intact substrates were excised directly from the gel. 
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The gel slice was then put into an RNase DNase free sterile Eppendorf tube and 
grinded using a sterile pestle (Argos Technologies Inc., Elgin, IL) into fine pieces. To elute 
the substrate out of the ground gel slice, 200 (iL DEPC treated water was added to the tube 
and the mixture was then transferred directly to a prepared PERFORMA® DTR (Dye 
Terminator Removal) Gel Filtration Cartridge (EdgeBio). The DTR columns are prepared 
by spinning the storage buffer in the column for 3 minutes at 850x g. To avoid breakdown 
of sensitive substrate, incubation under high temperature was eliminated from the 
instructed DTR gel filtration cartridge protocol. After loaded with ground gel mixture, the 
DTR gel filtration cartridge was spun down at 850x g for 3 minutes and eluted substrates 
were collected in a new 1.5 mL Eppendorf tube. The eluted substrate was then further 
subjected to phenol-chloroform precipitation. Dried radiolabeled RNA pellet was 
resuspended by adding 30 jiL DEPC treated water. The sample was either put in a -20°C 
freezer or subjected to scintillation counting. 
4.2.8 Assessing the endoribonucleolytic activity of positive hits 
The radioactivity (count per minute/ CPM) of the labeled RNA was typically 
measured using 1 jiL of the RNA sample. The radiolabeled RNA was further diluted to 
about 100,000 CPM / \iL before use in the endonucleolytic assay. A larger volume of 
reaction mixture was freshly made and divided into 18 fiL aliquots prior to the reaction. 
For each reaction, 1 fiL of 5' labeled substrate (100,000CPM) was incubated at 37°C in 18 
HL reaction buffer containing 0.2 (iL of 1M Tris (pH 7.4), 0.4 (J.L of 100 mM DTT, 0.4 jaL 
of 100 mM MgOAc and 17 |j.L of DEPC-treated water. Typically, about 0.5 - 1.0 fig of 
purified proteins were used in the assay and the typical incubation time for a concentration 
dependent experiment was 20 minutes. 
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4.2.9 Determination of RNA cleavage products 
1) Negative controls 
Two types of negative controls were included in every set of experiment (Input and 
None). "Input" negative control was prepared by adding 1 |iL of labeled substrate 
(100,000CPM) with 40 jxL RNA stop dye; the "None" negative controls differed from 
"Input" by addition of 18 (^L of reaction buffer. There was no incubation required for 
"Input", while "None" had different incubation times that matched up with the reactions 
incubated with the protein samples. In concentration dependent experiments, negative 
control reactions labeled as None 0' and None 20' represented incubation time of 0 and 20 
minutes, respectively. 
2) Markers 
To identify the cleavage sites generated by candidate enzymes, three markers were 
run in parallel (Alkaline hydrolysis ladder, RNase A and RNase Tl). 
Alkaline ladder 
The alkaline ladder was produced by incubating 7 \iL of labeled substrate 
(100,000CPM) with 1 \iL of lOx alkaline buffer and 2 jiL of DEPC treated water at 95°C 
for 3 minutes, and subsequently placed on ice for 1 minute before adding 20 |iL of RNA 
stop dye. 
RNase A 
RNase A ladder was produced by incubating 1 |iL of labeled substrate 
(100,000CPM) with 1 [iL lOx Structure buffer (Ambion, Austin, TX), 1 |iL of active 
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RNase A (0.025ng/ nL, Ambion, Austin, TX) and 7 \iL DEPC treated water at room 
temperature for 5 minutes. Reaction was stopped by adding 20 (iL of RNA stop dye. 
RNase T1 
RNase T1 ladder was prepared by incubating 1 of labeled substrate 
(100,000CPM) with 3 \xL of active RNase T1 (Roche Diagnostics Inc, Mannheim, Gemany) 
and 4 \iL of lx Sequence buffer (Ambion, Austin, TX) at room temperature for 5 minutes. 
Reaction was stopped by adding 20 nL of RNA stop dye. Components in each reaction in 
electrohphoretic assay are presented in Table 12. 
Table 12. Comparison of contents in each reaction in the endoribonucleolytic reaction 
assay. 
Reactions Rxn Buffer (fiL) Protein 
(HL) 
Radiolabeled 
Substrate 
(»L) 
Incubation 
Time 
Input (In) 0 0 1 0 
None (Non) 18 0 1 0-20 mins 
Reaction with 18 0.1 -2 1 0-60 mins 
protein Rg 
Ladders Alkaline 1 \iL lOx Alkaline buffer, N/A 7 3 min at 
hydrolysis 2 |*L DEPC water 95°C, 1 
min on ice 
RNase A 1 jxL lOx Structure 1 1 5 mins 
buffer, 7 \iL DEPC water 
RNase T1 4 jiL lx Sequence buffer 3 1 5 mins 
Note: "N/A" not applicable. 
4.2.10 Exoribonucleolytic Reactions 
1) Negative controls 
Negative controls include the "Input" and "None". "Input" negative control was 
prepared by adding 1 \iL of labeled Poly (A) 15 (100,000 CPM) with 40 jxL of RNA stop 
dye. Two "None" reactions with incubation time of 5 minutes and 20 minutes were 
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prepared with 18 jxL of reaction buffer and 1 |iL of labeled Poly (A))5 (100,000 CPM), and 
stopped by adding 40 jiL RNA stop dye. 
2) Candidate enzymes 
In each reaction, 0.5 jig of candidate enzyme (e.g. RPS2) was incubated in 18 [iL of 
reaction buffer in the presence of 1 \iL of labeled Poly (A) 15 (lOO.OOOCPM). Four reactions 
with different incubation time periods (0, 5,10 and 20 minutes) were made simultaneously. 
Reactions were stopped by adding 40 (iL of RNA stop dye. 
3) Snake Venom Phosphatase Reaction 
Snake Venom Phosphatase/SVP reactions were included as positive controls. 
Reactions with two incubation periods of 5 and 20 minutes were performed by mixing 1 (jL 
SVP (3x 10"5 units, Sigma, St. Louis, MO) with 12 jxL SVP buffer (99 mM Tris, 14 mM 
MgCh, 100 mM NaCl) in the presence of 2 jxL labeled Poly (A) 15 (100,000CPM). Reaction 
was stopped by adding 40 fj.L of RNA stop dye. 
4.2.11 3'- end radiolabeling of substrates 
The 3'- end labeling was performed by mixing 10 pmol of each substrate with 5 (iL 
3x pCp buffer in the presence of 1 fiL 100 jaM ATP, 10 pmoles y-32P-pCp (lOmCi/mL, 
Perkin Elmer), 1 \xL T4 RNA ligase and 1 |iL RNasin at 4°C overnight. The following day, 
reaction was stopped with 1 (iL of phenol and 20 |iL of RNA stop dye. The sample was 
loaded into a 15% polyacrylamide gel for gel purification. Gel purification procedure with 
the 3' labeled probes was performed as described in Section 4.2.7 (2). List of reagents used 
for 3'-radiolabeling is presented in Table 13. 
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Table 13. Components of reagents used in 3'-radioIabeling procedure. 
Reagents Ingredients 
3x pCp buffer 150 mM Hepes (pH 7.5), 60 mM MgCl2, 9.9 mM DTT, 30% (v/v) 
DMSO and 30 ng/mL BSA 
SVP buffer 99 mM Tris, 14 mM MgCl2, 100 mM NaCi 
lOx Alkaline 500 mM sodium bicarbonate pH 9.2 and 10 mM EDTA 
buffer 
RNA stop dye 9M Urea, 0.01% bromophenol blue, and 0.01% xylene cyanole FF 
'/2 x TBE 44.5 mM Tris-HCl, 44.5 mM Boric Acid, 1 mM EDTA (pH 8.3) 
4.2.12 Reactions with 3'- radiolabeled substrates 
Time dependent experiments were performed using 3'-radiolabled substrates 
miR155_13nt and Poly (A)I5. The reactions using 3'-radiolabled miR155_13nt were the 
same as the 5'-radiolabeled substrate. Time course experiments were performed. 
4.2.13 Sample loading and gel running 
All reactions, except for the alkaline hydrolysis digestion, had been normalized to 
equal CPM radioactivity. Since not all reactions had the same volume, the CPM per (iL 
concentrations varied. It was important to have the same radioactivity in all lanes to 
visualize and compare the reactions at different time points or with different protein 
concentration. Since the purpose of including the markers (Alkaline ladder, RNase T1 and 
RNase A reactions) was to assign the nucleotide position, the CPM count was not critical to 
their enzymatic function. The CPM of all lanes loaded in the 15% poly acrylamide gel, 
except for the markers, were normalized by adjusting the sample volumes loaded to the 
well. 
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After loading samples to each well, the gel was run at 15 mAmp for 1 hour and 30 
minutes in 0.5x TBE buffer. The gel was put in a -80°C freezer on one glass plate with a 
Phosphor Screen (Packard, Meriden, CT) on top immediately after the gel finished running 
to prevent the RNA fragment in the gel from diffusing. Exposure was typically done over 
night in the freezer. The following day, the gel image was scanned using a Cyclone 
Phosphor Imager (PerkinElmer, Waltham, MA). Post editing of the images was done using 
CorelDRAW software (Corel, Ottawa, ON). 
4.3 Results and discussions 
4.3.1 Induction test 
To ensure that we can proceed to the secondary screening step, we tested the 
inducibility of the selected positive hits (See Table 9) obtained from the primary screening 
step (Chapter 3). Clones from set 517A are shown as examples of the inducibility test 
(Figure 16). Only one of the two positive hits from 517A appears to be inducible. This is 
indicated by an extra protein band. 
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A01517 E17517 
1 2 3 4 5 
Figure 16. SDS-PAGE showing inducibility of positive hit from set 517A. Ten 
microlitres of each sample were loaded on the 12% SDS-PAGE gel. The gels were run at 
200 volts for about 30 minutes. indicates lane from uninduced clone, "+" indicates lane 
from clones induced with final concentration of 1 mM IPTG. Inducible recombinant 
protein bands are marked with an asterisk. 
Twelve of these selected positive hit clones mentioned in Chapter 3 were found to 
be detectable by SDS-PAGE. The clones that appeared to have extra visible band and were 
selected as inducible clones according to the SDS-PAGE were: C19512,123512, 013512, 
E17517, B01523, N01523, P09523, A15525, F06568, F20568, H06568, and N10568. The 
protein expression shown on the SDS-PAGE was ranked into four catergories by the 
thickness of the induced band: "high", "medium", "low" and "no" expression. However, to 
ensure the sufficient protein yield to work with in the later stage of the analysis, we only 
selected clones with inducibility ranking of "high" and "medium" for further purification: 
C19512,123512, E17517, B01523, N01523, A15525, andF20568 (Table 14). The 
inducibility of these clones along with negative control E01517 was further confirmed in 
the process of purifying the proteins for further analysis. 
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Table 14. Inducibility of positive hits that underwent induction test and their ranking. 
Clone MPMGp800.. Inducibility Ranking 
C19512 Medium 
E15512 No 
123512 Medium 
013512 Low 
023512 No 
A01517 No 
E17517 High 
B01523 Medium 
F01523 No 
L01523 No 
N01523 High 
P07523 No 
P09523 Low 
A15525 Medium 
CI 5525 No 
E15525 No 
G03525 No 
B06568 No 
D24568 No 
F06568 Low 
F20568 High 
H06568 Low 
J10568 No 
J16568 No 
N10568 Low 
Note: Names of the selected clones for further analysis are bolded. 
4.3.2 Purity of recombinant proteins 
To assess the purity and to determine size of the purified recombinant proteins after 
dialysis, 8 |xL of each sample was loaded onto a 12% SDS-PAGE gel. Protein purity was 
obtained by comparing the recombinant protein band, which was the most abundant protein 
band, to the protein background on SDS-PAGE (Figure 17). 
Some clones produced extra protein bands besides the main recombinant protein 
band. Clone A15525 appeared to have two protein bands on the SDS-PAGE (Figure 17, 
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Lane 5). The appearance of the lower band may be due to protein degradation. Other clones 
that have significant amount of extra bands were C19512, E17517, B01523, F20568 and 
the negative control E01517. 
Clone F20568 had a significant recombinant protein yield as shown on the SDS-
PAGE (Figure 17, Lane 2). According to the size estimated from SDS-PAGE (Table 16), 
the clone purified had a size close to the complete TCTP protein sequence. Lane 2 in 
Figure 17 shows that some larger proteins have been purified along with the recombinant 
protein. The sizes of these extra faint bands were estimated to be 108, 80, 60 and 40 kDa. 
These extra bands may be bacterial proteins that have mild affinity for the Ni-NTA column. 
1 2  3 4 5  6 7 8 9  1 0  
Figure 17. Purity of recombinant proteins after purification and dialysis. Eight 
microlitres of each purified recombinant proteins F20568, H06568, N10568, El 7517, 
B01523, A15525, C19512,123512, N01523 and E01517 (negative control) were run on a 
12% SDS-PAGE. Ten microlitres of protein marker were loaded to Lane 1; five microlitres 
of protein marker were loaded to Lane 10. *A15525 appears to have two protein products 
(Lane 5). 
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4.3.3. Secondary screen using fluorescence-based assay 
To confirm the results obtained from primary screen, a secondary screen was 
conducted using the similar fluorescence-based assay used in the primary screen. The 
fluorescence-based assay of each of the remaining seven clones was repeated four times 
with lug recombinant protein. Clone E01517 was included as the negative control. 
As shown in Figure 18,123512, F20568, C19512 and A15525 were found to be the 
top four active proteins in terms of their ability to cleave the miR155 substrate in all four 
trials of the fluorescence assay. 
On the other hand, El7517, BO 1523 and NO 1523 were found to produce results 
close to the negative controls (E01517, DNase I, dialysis buffer and DEPC H2O). Therefore, 
these clones were eliminated from further investigation. 
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Figure 18. Secondary screen for endoribonuclease activity. Purified proteins (l^g) of 
candidate clones were subjected to fluorescence assay using miR155 as a substrate. Clones 
are arranged from the highest to the lowest % RFU increase in the graphs. Two batches of 
each retested clones were purified and two trials were performed with each batch of clones. 
4.3.4 Identity and Integrity of Clones 
DNA sequences were translated into protein sequences from six reading frames 
with ExPASy. Identities were determined using BLASTx (NCBI) with DNA sequences and 
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BLASTp (NCBI) with translated protein sequences that contained 6 histidines (Table 15). 
The results of clone A15525 obtained from the DNA sequence and the translated protein 
sequence with 6 histidines did not match with each other. The identity of the A15525 DNA 
sequence was identical to a protein sequence from one of the reading frames that did not 
contain the 6-His tag. We determined that the insert of A15525 was shifted and out of 
frame with the His-tag. Therefore, this clone was eliminated from further analysis. 
Table 15. Identity, protein size and expected protein size of positive clones. 
Clone Protein Identity Expressed protein size Predicted 
MPMGp estimated by SDS- protein size 
800.. PAGE (kDa) 
CI 9512 Caskin-1 -15 
123512 40S Ribosomal Protein ~15 
S2 
A15525 No match (not in-frame) 19 
F20568 Translationally controlled 29 
Tumor Protein 
Note: Expected protein sizes were obtained from UniProt Database. "N/A" data not 
applicable. 
4.3.5 Characterization of candidate enzymes using electrophoretic endoribonuciease 
assay 
Translationally controlled tumour protein (TCTP. clone F20568) 
The RFU signal of recombinant TCTP (clone F20568) toward the fluorogenic 
substrate appeared to be lower than that of RPS2 (Figure 18). When subjected to 
electrophoretic assay, TCTP appeared to have ribonucleolytic activity toward both 
substrates (Figure 19 and 20). Major cleavage site generated by TCTP on miR155_13nt 
was 5UC, while weak cleavages were at 9GA, 11UA and 12AG (Figure 19). Appearance 
61 kDa 
32 kDa 
N/A 
19 kDa 
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of laddering pattern in both miR155_13nt (Figure 19A Lane 6) and miR155_24nt (Figure 
20A Lane 3-4) suggested that TCTP may possess exoribonucleolytic activity. 
None TCTP 
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Figure 19. Electrophoretic endoribonuclease assay and cleavage pattern of TCTP 
toward 5'-labeled miR155_13nt. (A) Increasing amount of TCTP and negative clone 
E01517 were tested against miR155_13nt for 20 minutes at 37°C in a standard 
electrophoretic endoribonuclease assay. (B) The RNA secondary structure of miR155_13nt 
shows the location of cleavage by TCTP. 
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Figure 20. Electrophoretic endoribonuclease assay of TCTP toward 5'-labeled 
miR155_24nt and "None" negative controls with and without 3U RNasin®. (A) 
Increasing amount of TCTP and 1 fig of negative clone E01517 were tested against 
miR155_24nt for 20 minutes at 37°C in a standard electrophoretic endoribonuclease assay. 
(B) The RNA secondary structure of miRl 55_24nt shows the location of cleavage by 
TCTP. (C) No difference is found between "None" with and without 3U of RNasin®. 
The substrate miR155_24nt appeared to be unstable in the electrophoretic assay as 
shown in Figure 20 A (Lanes 1 and 2), C and Figure 21 (Lanes 1 and 2). If the 
miR155_24nt folded as the most stable predicted structure (Figure 14B), 19G, 21G and 
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22G should have been paired as shown in Figure 14B. However, it was observed that the 
cleavage product at these G sites appeared in the RNase T1 ladder reaction. This 
observation led us to suspect that the substrate did not stay in one secondary structure 
constantly when the reaction took place. To determine the possibility of RNase A 
contamination in our assay, a time-dependent test was performed by incubating 1 \ih of 
labeled miR155_24nt in each reaction mixture with or without RNasin® Plus RNase 
Inhibitor (Promega, Madison, WI). One unit of RNasin® was shown previously to be able 
to inhibit the activity of 5ng of RNase A by 50% (Promega, Madison, WI). As observed in 
Figure 20C, miR155_24nt incubated with or without 3U RNasin® were significantly 
degraded at all of the U sites. The band intensities of these two conditions were almost 
identical. Addition of RNasin did not change the appearance of cleavage at U sites. 
Furthermore, the U site is a known natural self-cleaving site. Taken together, the cleavage 
product at U sites was not a result of contamination from common ribonuclease sensitive to 
RNasin®, such as RNase A, but maybe due to the unstable nature of the substrate. 
Caskin-1 (clone C195I2) 
Clone CI9512, which was identified to be caskin-1 or CASK interacting protein, 
did not exhibit strong expression (Figure 21, Lane 8). It also appeared to have extra bands 
being purified at 72, 60, 31 and 29 kDa along with the major band at 15 kDa. The 15 kDa 
band appeared to be more intense than the rest of the bands in Figure 17; it was more likely 
to be the recombinant protein bands. If this 15 kDa band was the recombinant Caskin-1, 
with the complete sequence of Caskin-1 being 157 kDa (1433 AA), the truncated form of 
caskin-1 that we purified was only 1/10 of the full length protein. 
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Based on the four fluorescence-based assay replicates, this truncated caskin-1 was 
able to generate an increase in RFU signal in all 4 trials of fluorescence assay comparing to 
the negative control E01517 (Figure 18). Caskin-1 appeared to cleave full length miR155 
substrate strongly at 4AU and 5UG (Figure 21). However, these strong cleavage bands may 
be due to the higher amount of substrate present as the intensity of the uncleaved substrate 
appeared to be higher in Lane 4 of Figure 21. We are aware of the uneven radioactivity 
presented in Figure 21, even though the amount of radiolabeled substrate for each sample 
was normalized before loading to the gel. 
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Figure 21. Electrophoretic endoribonuclease assay and cleavage pattern of Caskin-1 
and RPS2 toward 5'-labeled miR155_24nt. (A) Increasing amount of Caskin-1 and RPS2, 
and 1 fig of negative clone E01517 were tested against miR155_24nt for 20 minutes at 
37°C in a standard electrophoretic endoribonuclease assay. Stronge cleavage and removal 
of the phosphate group at 5U are shown on the gel. (B) The RNA secondary structure of 
miR155_24nt shows the location of cleavage by Caskin-1 and RPS2. 
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40S ribosomal protein S2 (RPS2. Clone 123512) 
As seen on the SDS-PAGE (Figure 17, Lane 8), RJPS2 had distinctive single bands 
with notably high purity. The size of this clone as estimated from the SDS-PAGE was 
about 15 kDa which was half of its predicted full length size of 32 kDa (293 AA). Based on 
the fluorescence assay in the secondary screen, RPS2 had the strongest activity to cleave 
the miR155 substrate by generating the highest percentage change of RFU and highest last 
RPU value in four trials. RPS2 was fiirther tested in vitro for both endoribonuclease and 
exoribonuclease activities using the miR155_13nt and Poly (A)is substrate. 
1) RPS2 cleaves 5' radiolabeled miR155_13nt 
As shown in Figure 22A, two different batches of RPS2 consistently cleaved sites at 
4AU and 5UC. To further assess the endoribonucleolytic activity of the stronger batch of 
RPS2 (Lane 3-4 of Figure 22A), we repeated the concentration-dependent electrophoretic 
endonuclease assay with this batch of RPS2 twice. A representative of the repeated 
experiment is shown in Figure 22B. A cleavage product at 5UC intensifies as the amount of 
protein in the reaction increases from 0.1 jig to 1 jxg (Figure 22B, Lane 3-4). A smaller and 
weaker cleavage product is shown at a slightly lower position of 4AU. It is suspected that 
this cleavage product is generated by a cleaving in between 4AU dinucleotide followed by 
a removal of the phosphate group. When compared with TCTP that cleaves strongly at 
5UC and weakly at 7GU, 9GA, 11UA and 12AG (Figure 19), RPS2 appeared to have a 
slightly different cleavage pattern. This evidence supports the argument that the cleavages 
seen in these two reactions were generated by two different enzymes. 
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phosphate 
Figure 22. Electrophoretic endoribonuclease assay and cleavage pattern of RPS2 
toward 5'-labeled miR155_13nt. (A) Increasing amount of two batches of RPS2 and 1 jig 
of negative clone E01517 were tested against miR155_13nt for 20 minutes at 37°C in a 
standard electrophoretic endoribonuclease assay. Both batches of RPS2 showed cleavage, 
but the first batch exhibit stronger activity. (B) Representative gel of repeated 
electrophoretic endoribonuclease assay using first batch of RPS2. (C) Cleavage locations at 
the predicted secondary structure of miR155_13nt. 
In the primary screen, RPS2 was selected as a positive hit that had cleaving activity 
towards thel3-nt miR155 substrate but not toward Oligo CU and CG. To further assess the 
substrate specificity observed in the screen, RPS2 was subjected to electrophoretic assay 
using a control substrate Oligo CU-aR. 
As anticipated, no cleavage appeared at 10CU site of the Oligo CU-aR (Figure 23). 
This was consistent with the primary screen observation that RPS2 was not able to cleave 
the CU dinucleotide. Interestingly, two very weak products were observed in between 5G 
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and 4G, and 4G and 3A. It is possible that the phosphate groups were removed from the 
cleaved products at 5GU and 4GG. 
It is interesting to note that RJPS2 cleaved between UC dinucleotide in 
miR155_13nt substrate but not in the Oligo CU aR substrate. Conversely, RPS2 cleaved 
between GU dinucleotide in Oligo CU_aR but not in miR155_13nt. Both of these sites are 
in the loop region of both substrates. Taken all together, it is difficult to discern any 
sequence specificity of RPS2. Further experimentation is needed to investigate the ability 
of RPS2 to cleave in a sequence-specific manner. 
Unlike the electrophoretic assay using miR155_13nt, there was no distinctive 
cleavage pattern of RPS2 on the full length substrate miR155_24nt (Figure 21). Although 
RPS2 were able to generate cleavage at 4AU and 5UG, this pattern is identical to those 
generated by Caskin-1. 
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Strong Weak Removal of 
phosphate 
Figure 23. Electrophoretic assay and cleavage pattern of RPS2 toward control 
substrate Oligo CU. Weak cleavage and removal of the phosphate group at 5G and 4G are 
shown on the gel. (A) Increasing amount of RPS2 was tested against Oligo CU for 20 
minutes at 37°C in a standard electrophoretic endoribonuclease assay. (B) Cleavage 
locations at the predicted secondary structure of Oligo CU. 
2) Time dependent effect of RPS2 on 5'-radiolabeled miR155_13nt 
To further study the ability of RPS2 to cleave miR155, the miR155_13nt was used 
as a substrate to investigate the enzyme kinetics, as it is more stable than miR155_24nt. A 
representative picture of the time-course experiment, which was repeated three times, is 
shown in Figure 24. Over a period of 40 minutes, a significant increase of cleavage product 
cut at 5UC was observed. Along with the 5UC cleavage site product, another time-
dependent cleavage was observed just one nucleotide shorter at 4AU. It was observed that 
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an extra band gradually appeared below the 4AU band as the incubation time increased. 
According to this observation, RPS2 appeared to be able to cut at 4AU weakly, and remove 
the phosphate group from the 3'-end of the cleavage product. 
We used the cleavage product at 5UC which was the most distinct decay product to 
determine the time course of the enzymatic activity which is shown in Figure 24A. A 
relative increase in radioactivity was obtained by measuring the band intensity of 5UC 
against a selected background. As observed, the enzymatic activity represented by the 5U 
band was increased over a period of 60 minutes. 
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Figure 24. Time-dependent experiment and kinetic analysis of RPS2 toward 5'-
labeled miR155_13nt. (A) 0.5 \ig of RPS2 were tested against miR155_13nt for 
increasing time period at 37°C in a standard electrophoretic endoribonuclease assay. B) The 
relative increase of radioactivity was indicated by the increase of band intensity at 5UC 
cleavage site. The intensity of band was measured using OptiQuant Software. The increase 
of band intensity was calculated by using the band intensity at a particular time point 
against the intensity of a randomly selected background. Results presented represent 
averaged data ± standard deviation from three experiments. 
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3) Effect of RPS2 on 3'- radiolabeled miR155_13nt 
To further investigate the cleavage pattern observed in electrophoretic assays with 
the 5'-labeled miR155_13nt was in fact due to the endoribonuclease activity of RPS2; the 
assay was repeated using a 3'-labeled miR155_13nt substrate (England et al. 1980). If 
RPS2 did possess only endoribonuclease activity, the cleavage product from 3'-labeled 
substrate would match the cleavage pattern observed in Figure 22. As shown in Figure 25, 
the corresponding 5UC dinucleotide cleavage was not observed in the 3'-labeled substrate. 
Interestingly, a laddering pattern of the substrate was observed, possibly indicating 
exoribonuclease activity in the 5'-3' direction. 
The experiment with 3'-labeled substrate was conducted only once to evaluate 
whether the cleavage patterns of 5'- and 3'-labeled substrates match with each other. 
Therefore no reliable conclusion could be drawn from this single experiment. Nonetheless, 
this experiment with the 3'-labeled substrate warrants future investigations on 
exoribonucleolytic activity of RPS2. 
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Figure 25. Time-dependent experiment of RPS2 toward 3'-labeled miR155_13nt 
showing weak exoribonuclease activity. (A) 0.5 fig of RPS2 were tested against 3'-
labeled miR155_13nt for increasing time period at 37°C in a standard electrophoretic 
endoribonuclease assay. Nucleotide labelling corresponds to the 3'-end of the cleavage site. 
"FL" uncleaved full length substrate. (B) Cleavage locations at the predicted secondary 
structure of miR 155 13nt. 
4) RPS2 showed weak exoribonucleolytic cleavage toward 3'- labeled Poly(A)i5 
substrate 
To further investigate the potential that RPS2 exhibits 5'-3' exoribonuclease 
activity, a 3'-labeled Poly (A) 15 substrate was used in the enzymatic assay. As observed in 
Figure 26, the 3'-radiolabeled Poly(A)is appeared to be degraded from the 5'-end in the 
presence of 0.5 ng RPS2 (Lane 5-7). All sample lanes with RPS2 (Lane 4-7) had the 
appearance of several bands with light intensity at the bottom of the gel, indicating that the 
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substrate was degraded in the 5'-3' direction. This suggests that RPS2 may have weak 
exoribonuclease activity. 
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Figure 26. Weak exoribonucleolytic activity by RPS2 toward 3'-labeIed PoIyA 
substrate. 0.5 (xg of RPS2 were tested against 3'-labeled Poly (A)i5 substrate for 
increasing time period at 37°C in a standard electrophoretic assay. Light intensity cleavage 
bands reveal the exoribonucleolytic activity of RPS2 toward 3'-labeled Poly A substrate. 
5) RPS2 showed weak exoribonucleolytic cleavage toward 5' labeled Poly(A)j5 
substrate 
To determine if RPS2 has 3'-5' exoribonuclease activity, we challenged 
recombinant RPS2 with 5'-radiolabeled Poly (A) 15 substrate (Figure 27). However the 
activity was detectable but very weak as compared to the strong cleavage by snake venom 
protein (SVP) that cleaved Poly A from the 3'-end. Directional exoribonucleolytic cleavage 
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was indicated by the ladder patterns of bands at different time points. SVP cleaves from the 
3'-end. The increase in the amount of shorter cleavage products was more pronounced 10 
minutes after the start of the reaction. RPS2 started to show visible pattern at 5 minutes; 
this pattern remained constant at 10 and 20 minutes, while the negative control E01517 did 
not generate any cleavage even at 20 minute time point. Thus, this observation suggests 
that RPS2 may have weak 3'-5' exoribonuclease activity towards Poly(A)i5. 
Figure 27. Weak exoribonucleolytic activity by RPS2 toward 5'-labeled PolyA 
substrate. 0.5 ng of RPS2 and negative control clone E01517 were tested against 5'-
labeled Poly (A) 15 substrate for increasing time period at 37°C in a standard 
electrophoretic assay. Light intensity cleavage bands reveal the exoribonucleolytic activity 
of RPS2 toward 5'-labeled Poly (A)i5 substrate. 
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Chapter 5 
General discussion 
5.1 General overview 
MicroRNAs have been receiving increasing attention as an important factor that 
controls expression of many genes including those implicated in cancer. Just like mRNAs, 
microRNA turnover is likely to be a crucial step in regulating their function (Parker and 
Song, 2004; Krol et al, 2010). Degradation of both mRNA and microRNA has been 
thought to be carried out mainly by exoribonucleases (Krol et al, 2010). However, 
exoribononucleases do not exhibit the specificity that endoribonucleases possess. Since 
very few human endoribonucleases have been characterized as compared to other model 
species such as E.coli, we hypothesize that there are many yet unidentified human 
endoribonucleases that can cleave mRNAs and the functional mature form of microRNAs. 
To date, no functional screen has been developed for endoribonuclease activity 
established outside our laboratory. The main goal of this MSc thesis was to develop a high-
throughput functional screening method to identify new human endoribonucleases that 
cleave miR155. Overall, this study has established a high-throughput experimental protocol 
to screen library of human recombinant proteins for possible ribonuclease activity. Using 
this protocol, we have identified a list of new candidate human ribonucleases. 
5.2 Significance of finding endoribonucleases that degrade microRNA 
The fate of a particular microRNA has great influence on the regulatory ability, as a 
single type of microRNA can control the expression of up to thousands of mRNA. For 
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example, the number of gene targets of human miR155 is approximately 5445 predicted by 
miRanda program (John et al. 2004). Many of these target genes also play essential roles in 
cancer. The oncogenic microRNA and tumour suppresser microRNA regulate the 
abundance of enzymes implicated in cancer by controlling the number of mRNA copy. In 
mammalians cells, microRNA acts on target mRNA very specifically by degrading only 
the complimentary target (Su, 2009). This unique feature of microRNA has been the key to 
its regulatory function. Thus, if we understand what the determining factors for selective 
microRNA degradation are (e.g., in specific tissue or in cancer cells), we can better 
understand the global regulation of gene expression. 
Studies on microRNA have been largely focused on the function and targets of 
microRNAs. To date, there has been limited information on how microRNAs are degraded. 
Only a handful of factors have been identified as the key players in microRNA turnover. 
They are exoribonucleases, RBP and adenylase (Das et al. 2010; Bail et al. 2010; 
Ramachandran and Chen 2008; Chatteijee and GroBhans 2009; Buratti et al. 2010). 
However, these enzymes do not possess sequence specificity, and thus can not explain the 
precise specificity of microRNA regulation. Therefore, there likely exist other key players 
such as endoribonucleases that are responsible for the highly regulated characteristic of 
microRNA turnover. 
5.3 The HTS functional screen 
The fluorescence-based assay, originally developed in our laboratory, has proven to 
be valid for the detection of the endoribonuclease activity of APE1 (Kim et al. 2010). To 
extend its further use, we have developed a functional screening-based method on the 
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principle of the previous fluorescence-based assay. An HTS functional screen using 
microRNA as the substrate has been developed during the course of this thesis. At the same 
time, we are aware of some potential problems using miR155_13nt for the sensitive 
fluorescence-based screen. Compared to the substrate design of Oligo UA, the 
miR155_13nt differs in several respects that may help us understand the potential problem 
in the screen (Kim etal. 2010). Using miR155_13nt, several improvements have been 
made during this project. 
First, the substrate used in the primary and secondary screen, miR155_13nt, is an 
all RNA design, whereas in Oligo UA there is only one ribonucleotide. There are 
advantage and disadvantage in having only one possible cleavage site in the substrate. 
Making a hybrid DNA-RNA substrate may help eliminate hits that have exoribonuclease 
activity. However, by doing this, potential proteins that cleave the double stranded part of 
the substrate will be eliminated. Moreover, if we limit the possible cleavage sites to the one 
or two particular ribonucleotide sites, we may fail to detect other potential 
endoribonucleases. 
Second, the secondary structure of miR155_13nt has a free energy of 9.2 kJ / mol, 
while it is - 9.1 kJ / mol for the Oligo UA based on the folded DNA structure. The lower 
the free energy, the more stable the structure is. The original rationale of using miR155 was 
the wide association of this microRNA in various cancers. As long as we continue to use 
miR155 as a template, the problems we encountered will still exist. 
Third, the Oligo UA has a stronger stem than miR155_13nt, by having more CG 
base pairs on a longer stem. An extra nucleotide was artificially added to the 5'- and 3'-
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end to create an extra CG pair at the end and a more stable structure. If we continue using 
the same microRNA, miR155, additional CG complimentary pair at the end may increase 
the stability. Nonetheless, we were able to obtain a list of positive hits despite the imperfect 
design of the original substrate miR155_13nt. 
We used the combination of selection method by last RFU (method 2 as described 
in Section 3.3.2) and elimination method that omit non-unique clones toward miR155 
(Section 3.3.3). Eliminating mutual positive hits with other oligonucleotides may not be the 
most suitable elimination method. As it may exclude true positive clones that cleave in 
between CG, CU or UA, only a portion of the potential true positives was covered and 
survived from the elimination. Furthermore, most of the positive hits that were selected 
using this elimination method generally had weak positive signals in fluorescence-based 
assay (Table 9). Therefore, future studies focusing on the positive hits using other selection 
and elimination methods can help us to determine which one is the best to eliminate false 
positives. 
5.4 From primary screen to secondary screen 
As summarized in Table 16, clones that showed positive results in both primary and 
secondary screen did show cleavage on RNA substrates in the electrophoretic assay (i.e. 
RPS2 and TCTP). Negative control, clone E01517, which did not appear to be cleaving the 
fluorogenic substrate in the secondary fluorescence-based assay, also did not show 
noticeable cleavage products in electrophoretic assay. 
The 24-nucleotide full length microRNA substrate was problematic because of its 
sensitivity to general degradation as observed at the U sites (Figure 20 and 21). Although 
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miR155_24nt required less free energy for forming the three possible secondary structures 
than the 13-nucleotide substrate (miR155_13nt), it was more sensitive to the natural 
cleavage sites. This also provides an answer as to why the full length substrate is not 
suitable for both fluorescence-based assay and electrophoretic assay. 
Table 16. Comparison between results from primary and secondary screen. 
Clone Primary Screen Post screening analysis 
MPM Secondary Electrophoretic 
Gp 
800.. Identity Signal Repeatable 
screen Assay 
13nt 24nt 
C19512 CASK interacting M N/A + N/A + 
protein (Caskin-1) 
123512 RPS2 M N/A + + + 
F20568 TCTP H Yes + + + 
E01517 Negative control - Yes - - -
Note: non-detectable level of activity; "N/A" data is not available or inconclusive. 
According to the results herein, both remaining candidates RPS2 and TCTP were 
positive from the primary screen to electrophoretic assay. As none of these clones have 
previously been shown to have ribonuclease activity, the results obtained in this study may 
be of importance and warrant father investigation. 
In Eukaryotes, RPS2 belongs to the 40S small subunit of 80S ribosome. The 
ribosome is a primary place for protein synthesis, where the 40S small subunit is 
responsible for holding the mRNA for translation. An in vitro study has found the 
correlation of RPS2 with increased cell proliferation (Kowalczyk etal. 2002). RPS2 is 
known to bind to mRNA as a ribosomal protein; it also binds to microRNA (Wang et al. 
2011). Recent study shows that RPS2 binds to pre-let-7a-l to prevent the expression of 
tumour suppressor microRNA let-7a in human prostate cancer (Wang et al. 2011). Future 
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studies can focus on finding out the RNA binding ability of RPS2 toward miR155 to add 
more information to its microRNA binding characteristic. Results shown in Chapter 4 
indicate that RPS2 is possibly a ribonuclease with both endoribonuclease and 
exoribonuclease activity. Combining these results together, it is suggested that RPS2 may 
preferably cleave after unpaired U and A closer to the 5'-end, and carry out weak 
exoribonuclease activity from both 5'-3' and 3'-5' directions after the endoribonucleolytic 
cleavage. These activities may play a surveillance role in keeping any aberrant mRNA 
from being translated. 
In the past, TCTP has been linked to cell growth and malignant transformation, and 
is generally more abundant in tumours (Bommer and Thiele 2004; Li et al. 2010; Tuynder 
et al. 2002). Interestingly, it is involved in a very rare cellular event called tumour 
reversion (Marce, 2004). The molecular functions of TCTP that have been identified so far 
include calcium-binding activity (reviewed in Bommer et al. 2002) and tubulin-binding 
activity (Kim et al. 2000). Although, the previous findings of RPS2 and TCTP suggest that 
they may be oncogenic and not involved in the turnover of oncogenic miR155, their 
identification in this project may suggest a more complex role they play in regulating 
miR155 function. Since RPS2 and TCTP had different cleavage patterns, it was very likely 
that they were two different enzymes. Thus, more careful work is still required to establish 
their specific function toward miR155. 
Some shared cleavage sites that RPS2 and TCTP generated led us to suspect that it 
might be a bacterial ribonuclease that caused the appearances of the same bands at 3 AA, 
4AU and 5UC of miR155_13nt. However, comparison of the purity of these three proteins 
(Figure 17) with the lower purity of the negative clone (E01517) made us question about 
100 
CH 5 GENERAL DISCUSSION 
this speculation. If the recombinant RPS2 and TCTP were contaminated, why would these 
cleavages not appear in the reaction using a less pure E01517? It would be worth retesting 
RPS2 toward 3'-labeled miR155 and confirm the results seen in Figure 27. Since TCTP has 
shown exoribonuclease-like activity toward miR155_24nt (Figure 20 A and B), conducting 
an electrophoretic assay with Poly (A) 15 substrate would help us to clarify this. In addition, 
tests like Electromobility Shift Assay (EMSA) would be helpful to determine whether 
RPS2 and TCTP have RNA binding ability toward miR155. 
5.5 Establishment of HTS procedure 
Compared to the original designed procedure, the established procedure to discover 
new human endoribonucleases has been slightly modified to maximize the chance of 
capturing novel enzymes. To summarize the modified HTS experimental procedure, a 
schematic diagram is shown in Figure 28. Several changes made to the initial design of the 
experiment (Figure 28). First, increasing the culture volume can improve the low yield in 
high-throughput protein purification. Second, repeating the primary screen and checking 
the reproducibility of positive hits may be a good tool to eliminate false positive. As shown 
in Chapter 3 and 4, reproducibility of a few clones supported this statement. Positive status 
of clone El 7517 was not repeatable in the primary screen and did not survive the 
secondary screen. Clone F20528 with repeatable positive signal in primary screen survived 
in the secondary screen and showed enzymatic activity in the electrophoretic assay. The 
negative signal of negative control E01517 was repeatable in primary screen and was 
confirmed in the electrophoretic assay. However, since primary screen of some clones was 
conducted once, there was not enough evidence to prove that reproducibility can predict 
true positive. Therefore, for the future screen, repeating the primary screen step can provide 
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more insights. Third, other selection methods still remain untested. Subjecting positive hits 
by other selection method to further analysis can provide information on choosing the best 
selection method. Fourth, substrate miR155_24nt is excluded due to it being unstable. 
Several further improvements can be made in future studies. First, using another 
library which has more complete information and full length clones will help to speed up 
the process of identifying positive clones. Second, now that this HTS procedure is 
established, screening for a higher number of clones will increase the chance of capturing 
true positive endoribonuclease. Third, using more than one type of microRNA as substrate 
to compare instead of Oligo CG, CU and UA can increase the chance of identifying new 
ribonucleases against selected microRNAs. 
The results presented in this thesis also allow us to know what to expect when 
conducting HTS screen using clones in hExl library and miR155 as a substrate, and 
difficulties that one may encounter when conducting future screen. In general, the 
established HTS procedure has allowed us to get one step closer to finding novel human 
endoribonucleases in vitro. 
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Figure 28. Schematic diagram summarizing the suggested procedure. Modifications: 
1. Culture volume increase from 2x ImL to 4x ImL; 2. Repeat the high-throughput primary 
screen three times to collect statistic data and determine if reproducibility is an effective 
tool to select true positive; 3. Testing positive hits using other untested selection methods 
can provide more information on choosing the best methods; 4. cDNA sequencing using 
primers pQE-F and pQE-Nhel-R instead of SP6 and T7; 5. Additional EMSA to find out 
whether positive hit possess RNA binding activity if ribonuclease activity is not observed. 
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5.6 Future directions 
This MSc project has led to several future research directions. First, the 
endoribonuclease activity of RPS2 and TCTP must be retested by repeating experiments 
with 3'-labeled substrate. Second, the combination of selection method using last RFU 
(second method as described in Section 3.3.2 (1)) and elimination method (eliminating 
non-unique hits toward miR155_13nt) may have not been the most effective way of 
selecting strong endoribonucleases as the fluorescent signal for both RPS2 and TCTP did 
not appear to be very high. Although we might have eliminated false positive hits by 
selecting unique hits, we may also have eliminated potentially highly active enzymes that 
cleave between CG, CU or UA. It is highly recommended to investigate the clones which 
exhibited high increases in fluorescence signal in future studies. In terms of screening for 
microRNA specific enymes, it may be of value to design a microRNA substrate with a 
deoxyguanosin monophosphate at one end and a deoxycytidine monophosphate at the other 
to stabilize the substrate and prevent capturing exoribonuclease since endoribonuclease is 
the main target of interest. 
5.7 Concluding Remarks 
This MSc project was intended to develop and validate a high-throughput procedure 
to screen a library of human recombinant proteins for endoribonucleases that cleave a 
microRNA substrate. Three major achievements and observations have been made during 
this project. First, a high-throughput functional screen has been successfully developed 
through a series of optimization experiments. Potential positive candidates were obtained 
from the screen. Second, a set of criteria has been established, which can be used to better 
narrow down the positive list to a shorter list with candidates that have high potential to be 
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endoribonucleases. With the selection criteria, future false positive candidates can be 
eliminated. Third, RPS2 was identified as a potential ribonuclease with both 
endoribonuclease and exoribonuclease activities. Future studies on RPS2 and the rest of the 
positive hits are expected to bring more insight in understanding the role of 
endoribonucleases in regulating microRNA functions. 
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